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The 213 bones in the adult body together form a protective network 
that serves a myriad of functions including calcium homeostasis, blood 
production through our marrow in the medullary cavity, as well as important 
protective and structural responsibilities.  Bone is similar to any other 
engineering material in that it is susceptible to damage accumulation through 
fatigue loading.  However, as bone itself is a “living material,” it can adapt, 
sense and repair itself based on cellular signals.  Under normal 
circumstances in a healthy patient, damage is repaired through a process 
where osteoclasts, specialized cells that destroy bone, target areas of damage 










bone forming cells which can refill excavated sites with new, healthy bone. 
In a condition where repair of this damage is inhibited, patients may 
accumulate large amounts of damage in their bones, which if allowed to 
proceed unchecked, can progress to catastrophic failure.  Recent clinical 
reports have suggested that bisphosphonates, one of the most common drugs 
used to treat low bone mass diseases like osteoporosis have also been 
associated with a small but significant number of low trauma, atypical 
femoral fractures with features that suggest damage accumulation in bone 
[1-6].   
Bisphosphonates are a class of anti-resorptive drugs which are used to 
target osteoclast destruction of bone in diseases where too much osteoclast 
activity leads to a reduced bone mass and increased risk of fragility fracture.  
Over the past 10 years, millions of osteoporotic women have taken these 
drugs for their condition [7].  Despite widespread clinical success, the 










tissue has not fully been determined [8].  Our ongoing research efforts seek 
to define the role of bisphosphonates on microdamage accumulation in the 
skeleton, and determine how bisphosphonate use may interfere with the 
natural tissue repair required to maintain a healthy skeleton capable of 
withstanding loads associated with activities of daily living.    
While rooted in fundamental principles of fracture mechanics and 
materials testing, the results of our studies will have broad clinical impact 
for diseases like osteoporosis, where bone structure deteriorates with patient 
age, as well as genetic diseases like osteogenesis imperfecta (OI), where 
mutations in proteins associated with bone adversely impact bone mass and 
fragility. Osteoporosis results in a decrease in bone mass, which in turn leads 
to an increase in fracture risk.  This disease affects over 10 million 
Americans, with an additional 34 million more estimated to have osteopenia 
or low bone mass on the verge of osteoporosis [9, 10] .  Bone mineral 










impacting those over 50 years of age. With the baby boomer generation 
continuing to have a strong impact on many of today’s policy decisions, the 
attention paid to osteoporosis will continue to increase.  In women over 45, 
osteoporosis is responsible for more hospital stays than diabetes, cancer, or 
heart attack, with an estimated $20 billion spent on direct health care 
services related to osteoporotic fractures [10].  As one can imagine, this will 
only continue to grow as people are living longer and remaining more active 
in their later lives.   
While osteoporosis is widespread throughout our aging population, OI 
typically affects approximately 1 in 20,000 young children [11], and the 
severity ranges from lethality in the perinatal stage to a barely detectable 
form of connective tissue disorder [12].  In both diseases, a disproportionate 
increase in osteoclast and osteoblast activity results in an overall imbalance 
favoring osteoclast destruction of bone [13, 14].  Thus, patients with 










bisphosphonate drugs to prevent the high bone destruction responsible for 
increased skeletal fragility and high fracture rates.  Using animal models 
representative of osteoporosis and osteogenesis imperfecta, our ongoing 
research seeks to determine 1) the impact of disease on the fracture 
toughness of bone material,  2) the effect of bisphosphonate therapy on the 
generation of bone microdamage and potential increase in bone brittleness 
following therapy and, 3) investigate the spatial distribution of 
bisphosphonates in proximity to microdamage as well as investigate the 
osteocytic response to extended bisphosphonate treatment.  Findings from 
these studies will impact the potential management of diseases of low bone 
mass, and may lead to alternative prevention strategies to reduce fracture 











1.2 Thesis Overview 
To accomplish these research goals, we have utilized a specific mouse 
model to replicate the material properties associated with low bone mass and 
collagen characteristics consistent with osteogenesis imperfecta.  The Brittle 
IV (Brtl/+) mouse model for OI contains an identical mutation present in a 
type IV OI patient, and replicates the disease in the form of bone fragility, 
moderately deformed skeleton, and high tissue brittleness [15].  
Furthermore, Brtl/+ replicates many of the cellular features characteristic of 
OI [16].  Wild-type animals are used as controls, to replicate bone with 
normal material properties unaffected by the collagen mutations present in 
OI, but likely susceptible to the effects of aging over time.   
As summarized below, the thesis was broken down into three parts.  
In our first study (Chapter 2), using linear elastic fracture mechanics 
principles, we established that Brtl/+ has a moderately reduced fracture 










brittleness using traditional four-point bending techniques.  Then, using an 
in vivo model of forearm limb loading, we were able to determine that Brtl/+ 
was highly susceptible to the generation and accumulation of skeletal 
microcracks under normal ambulation and during high applied load.  Our 
findings were featured on the cover of Bone [17] and were recognized by a 
Young Investigator award at the 2011 International Society of Biomechanics 
meeting.   
Given these findings of increased microdamage in models of OI, 
along with associations between microdamage accumulation and 
bisphosphonate usage, our second study (Chapter 3) aimed to assess the 
impact on bone mechanical integrity and the resulting fracture toughness 
following extended bisphosphonate treatment during the growing phase of 
the mouse. The use of bisphosphonates could ultimately lead to the 
prevention of damage repair, thus leading to decreased mechanical integrity 










increased fractures in certain sub-populations of treated patients.  We noted 
that bisphosphonates appear to impact the bone’s durability as indicated by 
matching microdamage and stiffness loss levels despite loading to a lower 
surface strain. This adverse result at high strains was countered with the 
positive result of no additional damage in unloaded treated limbs. 
Additionally, we noted a moderate decrease in fracture toughness following 
treatment. These findings suggest that bisphosphonates may have adverse 
effects at higher strains and may not be as detrimental at lower strains.  
Having established the impact of bisphosphonate therapy on the Brtl/+ 
mouse, we wanted to determine how bisphosphonates are spatially 
distributed within the bone tissue. This would help us to determine the 
cellular and local bisphosphonate delivery to microcracks and their 
surrounding cellular components following long term bisphosphonate 
treatment during the growing phase of the mouse.  Chapter 4 has focused on 










localization of bisphosphonate delivery in bone.  Using fluorescent analogs 
to bisphosphonates given to mice immediately following a bout of fatigue 
loading, we were able to demonstrate that these anti-resorptive drugs 
localize directly to bone microcracks themselves, as well as some of the 
surrounding cellular structures.  Additionally using a fluorescent apoptosis 
marker we monitored the local cellular response to microdamage to 
determine whether the cells responsible for signaling local bone repair are 
affected by local bisphosphonate delivery.  Interference with this signaling 
could potentially inhibit the needed repair of microdamage at the cellular 
level, as well as interfering with repair at the site of microdamage itself. We 
observed a decrease in osteocyte apoptotic signals in regions around 
microdamage in extended bisphosphonate treated bones. These findings may 
suggest multiple levels of regulation of microdamage repair, and the portion 










and osteocyte lacunae was recently presented at the 2013 Orthopaedic 
Research Society meeting.   
1.3 Societal Impact 
The efficacy of bisphosphonates in treating bone fragility [18-23] 
cannot be ignored. However, there is a prudent concern about the long-term 
effects of bisphosphonates on the inhibition of targeted repair of skeletal 
microdamage.  Extended bisphosphonate treatment has been correlated with 
observations of increased skeletal microdamage in animal models [24-27], 
which may in turn have detrimental effects on the bone’s mechanical 
integrity [24-26, 28].  To date, there has been no direct relationship to link 
extended bisphosphonate therapy with atypical, low-energy subtrochanteric 
femoral fractures observed in osteoporotic patients undergoing treatment 
[29, 30].  The results of this thesis suggest that the binding of 










may lead to arrested microdamage repair and could represent a contributing 
factor toward these femoral fractures.  
 Furthermore, these observations could also have strong implications 
for bisphosphonate treatment of fracture-prone osteogenesis imperfecta (OI) 
patients, since animal models suggest they have increased susceptibility to 
microdamage accumulation [17, 31].  With both OI and osteoporosis 
patients being increasingly susceptible to critical bone failure, treatment 
modalities need to be carefully assessed for their potential to affect damage 
repair.   
This thesis demonstrates that bisphosphonates may interfere with 
targeted microdamage repair directly by binding to microcrack surfaces and 
interfering with osteoclast repair at the site that needs it most.  Our results 
also suggest that bisphosphonates could interfere with targeted repair 
indirectly, because binding to surrounding osteocyte lacunae might interfere 










decreased fracture incidence is the critical rationale for treatment of patients 
with bisphosphonates, the implications of arrested microdamage repair for 
their quality of life are significant. 
Additionally, the potential of adverse mechanical effects of 
bisphosphonates are important to consider, since they are still the most 
common treatment modality prescribed to low bone mass patients. The 
moderately reduced fracture toughness properties measured in this work 
suggests that dosage as well as treatment duration still remains an important 
consideration when administering treatment to these patients. While 
bisphosphonates may improve bone mass, any adverse impact to bone on a 
microscopic level may inadvertently lead to increased fractures. Further 
studies are needed to determine ideal bisphosphonate treatment protocols 
that can be safely administered throughout growth and development, yet still 











Increased Susceptibility to Microdamage in Brtl/+ Mouse 
Model for Osteogenesis Imperfecta 
2.1 Introduction 
Osteogenesis Imperfecta (OI) is a genetic disease that adversely 
impacts bone mass and fragility, and produces other connective tissue 
manifestations in bone. It typically affects young children [11], and the 
severity ranges from lethality in the perinatal stage to a barely detectable 
form of connective tissue disorder [12]. OI is identified in approximately 1 
in 20,000 births and affects between 20,000 to 50,000 individuals in the 
United States [32]. Patients who suffer from OI typically have a mutation in 










[33]. Although most forms of OI are autosomal dominant, about 10% of 
cases have autosomal recessive inheritance of mutations in proteins 
responsible for post-translational modification of collagen, resulting in 
similar changes in the skeletal composition, structure and morphology to 
classical OI [34-36]. 
Studies have demonstrated a disproportionate up-regulation of 
osteoclast and osteoblast activity in OI patients, with an overall imbalance 
favoring osteoclast resorption [13, 14]. The mechanical and physiologic 
mechanisms responsible for this phenomenon are not fully understood.  
Increased bone turnover and fragility inherent to OI may be related to 
targeted repair of elevated levels of bone microdamage resulting from the 
brittle properties of OI.  However, there has been limited investigation on the 
presence and impact of microdamage in OI patients.  Animal models 
representing OI suggest that OI bone may be more susceptible to 










the Brittle IV (Brtl/+) mouse model for OI to determine the impact of an OI-
causing collagen mutation on the generation and accumulation of bone 
microdamage.  Brtl/+ has a Gly349→Cys (G349C) substitution in one 
col1a1 allele,  reproducing the genetic mutation found in a Type IV OI 
patient [38]. Brtl/+ demonstrates bone fragility, a moderately deformed 
skeleton, and a low ductility phenotype, accurately representing the 
biomechanical phenotype of the disease [15].  Furthermore, Brtl/+ features 
an up-regulation of osteoclast and osteoblast activity consistent with 
observations found in OI patients [16]. The direct cause of this upregulation 
has yet to be described. 
The primary goal of this study is to determine whether the Brtl/+ 
mouse is more susceptible to microdamage accumulation compared to wild 
type (WT) controls and to determine the correlation between fracture 
toughness and propensity to accumulate microdamage. We propose that a 










fracture toughness found in Brtl/+.  Understanding the role of this inherent 
bone matrix property will help elucidate the role of collagen mutations in 
governing susceptibility of OI bone to microdamage. 
2.2 Materials and Methods 
2.2.1 Murine Models 
A total of 18 male Brtl/+ and wild type WT (n=9 each) mice were 
bred from our colony and used in this study.  Brtl/+ mice have a mixed 
background of Sv129/CD-1/C57BL/6S and are bred by crossing 
heterozygous Brtl/+ with WT [38].  Mice were euthanized at 8 weeks of age 
in preparation for all loading experiments. All procedures used in this study 
were  approved by the University Committee on Use and Care of Animals 











2.2.2 In-Situ Strain Measurements 
The ulnar loading model [39] was used throughout this study to 
produce compressive loads and induce microdamage. This loading model 
has been shown to produce loads primarily within the ulna and not the 
radius, and has been shown to induce  microcrack formation within the ulna 
of rats [40]. The right forearms of mice were exposed to cyclic uniaxial 
compression loading across the olecranon and carpus process as described 
by others [40, 41]. Loading was done using a custom built servo-motor 
loader. Force-controlled, haversine, cyclic loading was performed at 1 Hz 
frequency while force and strain voltages were recorded using Labview 7.1 
software (National Instruments, U.S.A.). 
Six cadaver mice (n=3 Brtl/+ and n=3 WT) were used to record ulnar 
strains during loading in order to assess the level of force required to induce 
strains that would produce linear microdamage in compression (estimated at 










of the left forearm and the bones were further prepared using prescribed 
techniques [43] and commercial reagents (Vishay Micro-Measurements, 
U.S.A.) for the placement of strain gauges. Briefly, 100% ethanol followed 
by acetone was applied to the exposed ulna surface using a cotton tip 
applicator.  A catalyst (Catalyst-C) was then applied followed by a drop of 
adhesive (M-Bond 200). Single element strain gauges (EA-06-015DJ-120, 
Vishay Micro-Measurements, U.S.A.) were placed longitudinally as close to 
the lateral surface as possible of the ulna of both Brtl/+ and WT mice, near 
the mid-diaphysis. It has been confirmed experimentally [41], as well as 
through finite element modeling [44], that due to the geometry of the ulna, 
this area is the region of highest compressive strain and deformation during 
axial ulnar loading.  
Cyclic loading was performed continuously, and several rounds of 
data were collected for each mouse and analyzed using linear regression in 










genotypes (Figure 2-1). From these regressions it was noted that the loads 
that induced approximately 4000 micro strain were 2.71 ± 0.35 N for the 
Brtl/+ and 4.92 ± 0.04 N for the WT mice.     
2.2.3 Cyclic Loading 
A total of 12 cadaver mice (n=6 Brtl/+ and n=6 WT) were used for 
cyclic loading. To induce microdamage, a similar loading construct and data 
recording protocol was used as described for in-situ strain gauging, with the 
exception that force and actuator displacement were recorded using Labview 
7.1 software. Cyclic loading was performed in situ in order to accurately 
simulate future in-vivo experiments involving sedated animals. The 
contralateral forelimbs were not loaded and were used as controls to assess 
baseline levels of microdamage in the bone matrix. Each specimen was 
allowed a 5 minute (300 cycles) period of dynamic pre-conditioning in order 
to mitigate the effects of soft tissue compliance and thus isolate and account 










degradation [44]. This time also afforded the opportunity to gradually ramp 
up the force amplitudes for each forearm to produce the required range of 
strains, as necessitated by the intrinsic differences in bone size between 
animals.  Bones were then cyclically loaded for 30 minutes (1800 cycles) at 
force-controlled loads that produced approximately 4000 microstrain (µε) 
based on data collected in the in situ strain gauge experiments (Figure 2-2). 
Minimal compressive loads on the reversal phase of loading of 
approximately 2.45 N and 1.34 N for WT and Brtl/+ mice, respectively, 
were used to ensure that platens remained in contact with the bone during 
the unloading segment. Post hoc calculations showed that WT mice 
displayed compressive strains ranging between a minimum of approximately 
418.4 µε during the unloading segment and  approximately 4010.8 µε 
(approximately 5N) at maximum loading, whereas Brtl/+ exhibited strains of 
541.7 and 4039.1 µε (approximately 3N) during unloading and loading 










was recorded for each bone using a linear variable differential transformer 
(LVDT). Loss of stiffness for each bone was determined using Eq. (1), 
which was previously used by Bentolila et al. [40] as a surrogate for 
effective stiffness loss.  
 
Equation 2-1 





                                                                           
 
where Lo is the initial length of bone and L is the final length of the bone. 
The initial length was always measured at the end of the dynamic pre-
conditioning period (300 cycles) while L was measured when loading was 
complete. Both Lo and L were measured using the calibrated external LVDT 










2.2.4 Microdamage Quantification 
After loading, the loaded (right) and unloaded (left) forelimbs were 
excised and stained with 1% basic fuchsin using an established protocol [45] 
and rinsed in 100% ethanol. Samples were subsequently embedded 
undecalcified in poly methyl methacrylate (PMMA) for histology. Using a 
Buehler Isomet diamond-blade saw, 400 µm sections were then cut 
transverse to the longitudinal axis of the ulna. These sections were mounted 
on a plastic microscope slide and polished to a final thickness of 100 µm.  
Sections were cover slipped and examined with a confocal microscope 
(Zeiss LSM 510-META Laser Scanning Confocal Microscope, Carl Zeiss 
MicroImaging, Inc., Thornwood, NY, U.S.A.) at 63x magnification using a 
Helium Neon 1 (HeNe1) laser (543 nm) with a Texas red/rhodamine filter. 
Slides from the mid-diaphyses of each ulna were analyzed to quantify 
microdamage. Images were taken for the entire 100 µm thick cortical region 










4.2.0.121, Carl Zeiss Micro Imaging, Inc.) to quantify linear microdamage 
within the cortical region. Cracks that were positively labeled with basic 
fuchsin dye were deemed as damage-induced during loading. Diffuse 
damage was not assessed in this study. The following parameters were 
measured throughout the entire cortical bone region of each section: number 
of microcracks (#), bone cortical volume (B.Vol., mm3), microcrack 
numerical density (Cr.Dn., #/mm3) and microcrack surface density 
(Cr.S.Dn., mm/mm3).  
2.2.5 Fracture Toughness 
To correlate microdamage with fracture toughness, femurs from each 
mouse were prepared and tested according to techniques established by 
Ritchie [46]. This technique utilizes linear elastic fracture mechanics 
(LEFM) principles and a self-induced starter notch to measure the bone’s 
resistance to fracture (fracture toughness). For regular mechanical testing of 










the initiation point of fracture [47]. This starter notch is typically induced by 
a fatigue loading technique; however, due to the small geometry of mouse 
bones, this procedure is not optimum. Studies have shown that accurate 
fracture toughness data can be attained from razor sharpened micronotches 
[48] and this technique has been deployed for small animal studies [46] 
(Figure 2-3). Using this technique will provide us with a true mechanical 
measure of the bone’s inherent fracture toughness, without the viscoelastic 
influence of soft tissue.  
The left femora of Brtl/+ (n=6) and WT (n=6) were harvested, cleaned 
of soft tissue, and stored frozen at -20°C in gauze soaked in Lactated 
Ringer’s Solution (LRS) until testing. Bones were machine-notched through 
the posterior cortex at the mid-shaft using a micro milling device with a 
cutting radius of 0.01 inches. Notches were then sharpened using a custom 
rigged mounted razor blade, pasted with 1 µm diamond polish (Struers). 










were made using a micro mill to approximately 1/3 of the bone diameter.  
This notching procedure typically produces a reproducible sharpened notch 
root radius of approximately 10 µm [46, 48] .  
In preparation for three-point mechanical bend testing, the femoral 
heads were removed, while the condyles were left intact. This was done to 
maintain stability within the three-point bending apparatus. Femurs were 
thawed in LRS soaked gauze at room temperature to preserve moisture 
content until they were ready for testing. Specimens were loaded to failure in 
three-point bending at 0.001 mm/s using a servohydraulic testing machine 
equipped with a 220N load cell (858 MiniBionixII Material Test System; 
MTS Systems Corporation, Eden Prairie, MN, USA) in accordance to 
ASTM standards [47, 49] and other established protocol [46]. During three-
point bending, the specimens were placed such that the posterior surface was 
in tension and the anterior surface was in compression with the top loading 










length of 4.5 mm was used in testing. Load and displacement values were 
recorded throughout the experiment using integrated Material Test System 
data acquisition software (858 MiniBionixII Material Test System; MTS 
Systems Corporation, Eden Prairie, MN, USA).   
After mechanical testing, fractured bone specimens were fixed in 70% 
ethanol, defatted in toluene under vacuum for 24 hours, and cleared of soft 
tissue with 2% potassium hydroxide for 12 hours. The specimens were 
dehydrated by immersion in a graded series of alcohols (50%, 70%, 95% 
and 100%) and coated with carbon [37].  Specimens were imaged by SEM 
to determine the transition from stable to unstable crack growth (Figure 2-
4).  Fracture toughness, Kc, was measured using solutions for 
circumferential through-wall cracks established for cylindrical pipes [46, 50, 
51]. Both the maximum load and the crack instability techniques were used 
to determine fracture toughness values [46]. All measurements used in the 










SEM images of fracture sites using the public domain software ImageJ 
(National Institutes of Health).  
All measurements of thickness and radii were measured on the 
fracture surface of each specimen i.e. the non-notched surface as previously 
instructed by Ritchie [46]. Cortical thickness was taken as an average 
measurement of 6 different thicknesses measured at different points along 
the fracture surface. The centroid for each specimen was determined by 
drawing a line parallel to the notch that was half the bone’s diameter. This 
line represented the major axis. Another axis that was rotated 90 degrees to 
the first was also placed at half the bone diameter. This line represented the 
minor axis. The intersection of these perpendicular lines represented the 
centroid of the bone (Figure 2-6).  In determining the stable to unstable 
transition region, the SEM was used in backscatter mode. The difference in 
morphology was used to determine the transition. The stable region is 










whereas the unstable region has a more spongy appearance. Half-crack 
angles (2θ) were determined by measuring the included angle (maximum 
load technique) which is formed from the centroid to the notched surface, 
and with the excluded angle (instability technique) which is formed from the 
centroid to the stable to unstable transition region (Figure 2-6). 
2.2.6 Statistics 
Effect of genotype on percent stiffness loss, crack numerical density, 
crack surface density, and fracture toughness values calculated using either 
the maximum load or instability technique were compared using a non-
parametric Mann-Whitney test (GraphPad Prism 4.0) to account for small 
samples sizes.  Linear regression between microdamage data and fracture 
toughness data was performed across genotypes and loading conditions.  In 
all tests, significance was attributed to p<0.05.  All data is presented as mean 













2.3.1 Brtl/+ ulnae demonstrate lower stiffness loss during loading 
Whole bone loss of stiffness for each forearm was measured via 
LVDT during cyclic loading according to Equation (1).  While Brtl/+ and 
WT ulnae were loaded with matching surface strains, Brtl/+ demonstrated a 
lower percentage stiffness loss (1.77 ± 0.84%) compared to WT (3.56 ± 
1.29%) over the 35 minute load period (Figure 2-7).  
2.3.2 Brtl/+ ulnae have more microdamage than WT 
Non-loaded control limbs from Brtl/+ demonstrate significantly 
increased linear microcrack numerical density (217%) and microcrack 
surface density (354%) compared to their WT counterparts (Figure 2-8A,B).  
In loaded limbs, Brtl/+ demonstrates a 220% increase in crack numerical 










8A,B).  Linear microdamage was observed on the tensile and compressive 
(medial and lateral) sides of the ulnar cortices.  While some cracks were 
oriented circumferentially, others ran through the cortex and spanned 
multiple lacuno-canalicular structures (Figure 2-9). 
2.3.3 Brtl/+ femora  display a moderate trend toward reduced fracture 
toughness compared to WT 
Femora paired with loaded ulnae from within the same animal were 
tested for fracture toughness.  During sample preparation and testing, 2 
Brtl/+ and 2 WT specimens were lost due to errors in the notching process or 
due to premature fracture during three-point bending.  Using the maximum 
load technique, which assesses fracture toughness based on the initial notch 
geometry and the maximum load encountered during three-point bending, 
WT femora displayed average Kc values of 3.36 Mpa√m whereas Brtl/+ 
specimens had Kc values of 2.73 Mpa√m (p=0.486) (Figure 2-10A). The 










unstable and stable crack growth, and showed a more sensitive 35.4% 
difference in Kc values between genotypes (WT 3.79 Mpa√m; Brtl/+ 2.44 
Mpa√m) (p=0.057) (Figure 2-10B).  During crack instability calculations, 
four cases (3 WT and 1 Brtl/+) demonstrated half-crack angles that exceeded 
the range of values deemed valid (Θ/π = 0.611) for thick wall cylindrical 
pipe circumferential analysis (Θ/π = 0.663, 0.645, 0.707, 0.756) [46].  These 
represent specimens that are more ductile than the equation allows for 
accurate calculation.  In those cases, by setting Θ/π to 0.611 for these 
specimens, an additional lower bound estimation of instability fracture 
toughness was estimated, resulting in a 31.4% difference in fracture 











2.3.4 Microdamage is differentially regulated by fracture toughness in 
loaded vs. unloaded ulnae 
The inability of maximum load fracture toughness values to be 
predictive of genotype precluded it from regression analysis.  Fracture 
toughness measured by the instability technique was only predictive of crack 
numerical density and crack surface density when genotypes were pooled 
into separate regression models for loaded and unloaded ulnae (Figure 2-
11).  Brtl/+ and WT ulnae showed a negative correlation between instability 
fracture toughness and crack surface density (R=-0.85, p=0.01) and 
instability fracture toughness and crack numerical density (R=-0.72, 
p=0.04).  Brtl/+ and WT unloaded ulnar instability fracture toughness also 
showed a strong negative correlation with crack surface density (R=-0.72, 
p=0.04) and with crack numerical density (R=-0.87, p=0.01).  While there 
was no significant difference between the regression slopes of unloaded and 










between instability fracture toughness and crack surface density varied 
depending on whether ulnae were loaded or unloaded (p=0.02, Figure 2-
11B). 
2.4 Discussion 
Currently, little is known about OI regarding the susceptibility of 
bones to produce and accumulate microdamage compared to bone with 
normal collagen. High propensity to form and accumulate microdamage may 
play a role in the inherent fragility and remodeling behavior seen in OI 
patients. This study utilized the Brtl/+ mouse to investigate the correlation 
between propensity to form microdamage and the inherent fracture 
toughness of bone formed with an OI-causing mutation.  
Brtl/+ ulnae subject to normal cage activity demonstrated a larger 
amount of cortical microdamage than WT controls.  Furthermore, following 
35 minutes of axial compressive loading matched for bone surface strains 










despite a greater resistance to whole-bone deformation. Femoral fracture 
toughness tests show a trend toward differences in Kc values between Brtl/+ 
and WT, although these differences were not statistically significant. These 
fracture toughness values correlate well with levels of microdamage 
quantified in intact and mechanically-loaded limbs.  
The moderate reductions in fracture toughness found in Brtl/+ are 
consistent with reductions found in other mouse models of matrix 
insufficiency.  Osteopontin deficient mice have reduced work to fracture 
(59%) and post-yield deformation (39.6%) compared to WT controls [52], 
and 8 week OPN -/- mice show a corresponding 30% decrease in instability 
fracture toughness compared to WT [53].  Brtl/+ has shown similar 
reductions in work to failure (59%) and post-yield displacement (42%) [15] 
and a 35% decrease in fracture toughness in the present study.   
The amount of energy that a material can withstand before the onset 










mechanics [54] [55].  In the present study, instability fracture toughness 
from Brtl/+ showed a strong trend, but not statistically significant reduction 
compared to WT.  This suggests that the lower work to failure and post-yield 
energy associated with Brtl/+ may represent both an inability to prevent 
onset of critical microcracking, as well as a reduced resistance to crack 
growth toughness which was not directly measured in this study.  Crack 
growth appeared to be differentially regulated by instability fracture 
toughness between loaded and unloaded limbs in this study, whereas crack 
number had a similar relationship to instability fracture toughness whether 
limbs were loaded or not.  Other OI models have implicated collagen 
integrity as a potential cause for OI bone’s inability to withstand damage 
accumulation. Oim mice have demonstrated low work to failure and require 
fewer cycles to generate equivalent amounts of microdamage compared to 
WT counterparts [31].  The Mov 13 mouse displays a purely quantitative 










demonstrates a 61% decrease in post-yield displacement [37].  Furthermore, 
the cortical tissue components integral in the prevention of damage 
accumulation are severely compromised in Mov 13, leading to increased rate 
of damage accumulation and a decrease in the number of cycles to failure 
when compared to WT [57]. It is evident that mutations involving type 1 
collagen production have significant impact on the microdamage 
accumulation, fatigue strength and overall mechanical properties of bone. 
Our in-situ strain gauge data shows that the Brtl/+ ulnae required 45% 
less load to induce the prescribed 4000 µε. This is likely due to the 
geometric differences in bone sizes reported in other load bearing bones 
such as the femur [13]. X-ray images of ulnae demonstrated a small decrease 
in Brtl/+ lengths compared to WT (1.8%) but a 25% decrease in diameter 
(data not shown). However, during loading, Brtl/+ ulna showed a greater 
resistance to whole-bone deformation, likely due to previously observed 










[58] thus leading to a less compliant bone compared to its wildtype 
counterpart. This increase in tissue mineral density is in line with the more 
brittle phenotype, that has been previously displayed in Brtl/+ [15] and in 
humans [11, 59, 60]. Our observance of higher linear microcracks in Brtl/+ 
is supported by numerical probabilistic models, that show that higher 
mineralization in bone will facilitate the formation of linear microcracks 
[61].  This is further supported by experimental studies on dogs treated with 
bisphosphonates, which demonstrate bones had increased tissue 
mineralization with treatment but became more prone to a concomitant 
increase in microcracks and reduced energy absorption [62]. Despite Brtl/+ 
specimens displaying a lower loss of stiffness, we still observe higher levels 
of microdamage. Previous studies have shown that there appears to be a 
difference in the surrounding bone matrix mineral composition between 
microdamaged areas and undamaged areas [63, 64]. These studies provide 










is released to the surrounding bone matrix of Brtl/+ and WT specimens, thus 
potentially explaining our high microdamage but low stiffness loss 
observations in Brtl/+ specimens. 
A significant amount of linear damage was observed at the tensile and 
compressive (medial and lateral) sides of the samples cortices and were 
oriented circumferentially.  Previous studies of rat bone cyclically induced 
crack numerical densities ranging from 0.2 to 4.0 /mm2 and crack surface 
densities of approximately 0.2 mm/mm2 [40, 65].  In the present study, crack 
numerical densities ranged from 20 to 300/mm3, while surface densities 
were between 1 and 34 mm/mm3.  The volumetric approach used in the 
present study accounts for these differences, as crack size and length were 
quantified through a 100 µm volume thickness, rather than a single section 
from the mid-span of the specimen.  This volumetric approach minimizes 
the influence of surface polishing artifacts on the overall results, and 










verifying this approach, crack surface densities of several samples were 
analyzed on single optical slices. Results demonstrate that values from a 
single slice approach are within range of those observed by previous studies 
(data not shown).  
Differences in fracture toughness were observed in our study, and 
were more noticeable using the instability technique.  These differences 
reflect changes in half-crack angles between Brtl/+ and WT, where, on 
average, Brtl/+ specimens had smaller half-crack angles closer to the 
original starter notch, while WT specimens, with a more ductile fracture, had 
stable crack propagation further away from the starter notch.  During these 
calculations, there were 4 cases (3 WT and 1 Brtl/+) where the half crack 
angles exceeded the range of angles deemed valid for accurate assessment of 
fracture toughness [46], indicating specimens that were more ductile than the 
equations can accurately calculate.  To assess any potential error associated 










permissible half crack angle of 1.9195 radians as an upper limit estimate. As 
such, the determined value of Kc for these re-calculated toughness values 
effectively represents a lower bound estimation of instability fracture 
toughness for ductile specimens.  In this case, a 31.4% difference between 
Brtl/+ and WT Kc values remained (Brtl/+ 2.44 Mpa√m and WT 3.56 
Mpa√m) despite these estimated parameters. Furthermore, similar 
correlations between microdamage and instability fracture toughness were 
observed regardless of whether the original or re-calculated data was used, 
suggesting a minimal effect of these outliers on our conclusions. The lack of 
significance in our fracture toughness data may also suggest that a lower 
resistance to crack growth toughness, and not crack initiation as measured,  
may be the more prevalent underlying difference between Brtl/+ and WT 
fracture toughness.   
This study aimed to investigate the susceptibility of OI bone to 










play in the inherent fragility and remodeling behavior seen in these patients. 
Although both osteoblast and osteoclast activity is increased in these 
patients, there is an imbalance in bone remodeling in favor of osteoclast 
activity [11], which ultimately leads to a compromised bone structure. It is 
unknown however as to what is the cause for this up-regulation in 
remodeling behavior seen in OI patients.  
As microdamage levels increase in a healthy individual, the inherent 
remodeling processes of bone are activated for microdamage repair [66].   
The increased remodeling activity seen in OI patients may be related to the 
extent of microdamage present in their bones, resulting from the 
compromised collagen inherent to the disease.  Brtl/+ mice demonstrate an 
increase in osteoclast number and function compared to WT [16], and the 
current findings demonstrate a correlative increase in propensity to generate 
and accumulate microdamage in the bone.  While the cellular asynchrony 










in osteoclast precursors in Brtl/+ marrow [16], the RANKL/OPG ratio is 
unchanged and the factors regulating increased osteoclasts have yet to be 
described.  Further in vivo loading experiments will determine whether 
generation and accumulation of skeletal microdamage in Brtl/+ is 
responsible for these increased remodeling rates.  
A widespread treatment for the high turnover and low bone mass 
condition of OI is bisphosphonate therapy. Bisphosphonates function by 
reducing bone turnover and increasing skeletal mass, but do not target the 
underlying genetic abnormalities associated with the disease [58]. While the 
intention for OI treatment with bisphosphonates is to increase skeletal mass,  
they may concomitantly prevent targeted repair from occurring. It has been 
shown that downregulation of bone remodeling with bisphosphonate therapy 
results in an increased accumulation of skeletal microdamage in other 
models [24-27], subsequently resulting in a reduction of skeletal mechanical 










therapy in a low-fracture toughness skeleton prone to the generation of 
microdamage have not yet been described.     
In conclusion, our studies have shown that the Brtl/+ mouse model for 
OI is more susceptible to microdamage accumulation than age-matched WT.  
These data suggest the possibility that OI patients may engender larger 
degrees of damage due to the inherent collagen mutation. With the increase 
in damage comes an additional risk of lowered resistance to bone fracture. 
Increased microdamage and reduced fracture toughness observed in the 
Brtl/+ model for osteogenesis imperfecta suggests that microdamage may 
play a significant role in contributing to bone fragility and increased 
remodeling associated with OI. These findings have strong clinical 













Figure 2-1: Typical linear regression force-strain curve 
Graph showing the loading portion of the force-surface strain relationship for a WT 
specimen being monotonically tested in compression. 
 
 






























Figure 2-2: Sinusoidal loading pattern 
Figure representing the sinusoidal cyclic loading pattern that bones were exhibited 
to. Strains oscillated between minimum compressive strains of approximately 450 













Figure 2-3: MicroCT image of starter notch 

















Figure 2-4: SEM image of notched surface 
SEM image showing the notch, stable crack growth and unstable crack growth region 











Figure 2-5: Half-Crack angle determination 
SEM image showing the method used to determine the centre of images. The first line 
was drawn parallel to the notch at about half the thickness of the bone. The second line 











Figure 2-6: Schematic of fracture surface 
The top schematic displays the setup of the femur for 3-point bend testing where 
S represents the span of the bottom anchors (4.5 mm) and P represents the applied load. 
Notice that the femoral head has been cut off and the sharpened notch is placed at the 
mid-diaphysis. The bottom schematic represents a cross-section of the femoral cortex, 
which displays the measurement of the half-crack angle for determining the fracture 
toughness Kc using the maximum and instability methods. The displayed included and 












Figure 2-7: Average stiffness loss for each phenotype  
Average stiffness loss for each phenotype after 5 minutes of 1Hz cyclic pre-conditioning 
loading and 30 minutes of 1Hz cyclic loading. Brtl/+ specimens display lower loss of 
stiffness (1.77%) when compared to their WT counterparts (3.56%) under cyclic loading. 













Figure 2-8: Microdamage levels in Brtl/+ and WT specimens 
Summary data quantifying the amount of microdamage seen in both loaded and unloaded 
Brtl/+ and WT specimens. The crack numerical density (Cr.Dn), which measures the 
number of individual linear microcracks along the specimen surface area for both loaded 
and unloaded Brtl/+ and WT specimens, can be seen in (A). The crack surface density 
(Cr.S.Dn) which measures the amount of damaged tissue across the specimen surface 











Figure 2-9: Confocal images of microdamage 
Confocal photomicrographs of basic fuchsin stained cross sections obtained from the ulna 
mid-diaphysis of an unloaded Brtl/+ specimen (A) and a loaded Brtl/+ specimen (B). 
Linear microcracks in the cortex are stained with basic fuchsin. Scale bar 20 µm with a 












Figure 2-10: Fracture toughness values for WT and Brtl/+ specimens 
Graph showing the average fracture toughness values for WT and BRTL/+ specimens 
tested using the maximum load(A) and instability techniques(B) described by Ritchie 
[46]). There was an 18.6% difference noted with the maximum load technique (p=0.486) 
whereas as 35.4% difference was noted with the instability technique (p=0.057). 
 














Figure 2-11: Pooled fracture toughness correlations 
Correlations between instability fracture toughness values and crack numerical density 
(A) and crack surface density (B). Instability fracture toughness was negatively correlated 
with loaded and unloaded ulnar CND and CSD. Whereas the slopes governing this 
relation between Kc and CND were the same between loaded and unloaded limbs 
(p=0.4), the slopes were significantly different in the relationship governing Kc and CSD 





























The Effect of Bisphosphonate Therapy on 
Microdamage Accumulation in the Brtl/+ Mouse Model  
3.1 Introduction 
Bisphosphonates are a potent anti-resorptive drug commonly used to 
treat diseases of low bone mass or high bone turnover such as osteoporosis 
[67], Paget’s disease [68], and most recently osteogenesis imperfecta 
(OI)[69]. Since its introduction as a treatment option for pediatric OI 
patients, there has been an increased interest in our understanding of their 
effects in the growing skeleton. OI, which is commonly known as “brittle 
bone disease”, is a heritable connective tissue disorder that is attributed to 










turn impacts the skeleton structurally and morphologically. Common traits 
of the disease include decreased bone fragility, increased brittleness and 
fracture incidence, and an up-regulation in bone remodeling [11, 14, 71].  
Bisphosphonates aim to improve bone mass, and strength, but do not 
affect the defective type I collagen. Instead, bisphosphonates increase bone 
mass by inhibiting osteoclast-mediated bone resorption through decreased 
osteoclast recruitment, promotion of apoptosis of mature osteoclasts [72, 
73], and possible inhibition of apoptosis of osteocytes and osteoblasts [74]. 
Treatment of OI patients with bisphosphonates has shown to be especially 
promising in reducing vertebral fracture rates [75, 76] but has not 
demonstrated a notable functional improvement in long bones [75, 77, 78]. 
Animal studies have played a key role in determining the effects of 
bisphosphonates on skeletal integrity.  While bisphosphonates are used to 
increase bone mass, there have been reports in several animal models that 










81], which subsequently leads to a decrease in mechanical integrity of the 
bone [80-82]. Although there have been studies that have investigated the 
effects of long term bisphosphonate treatment in OI mouse models [58, 83, 
84], none have presently looked at microdamage levels following treatment.  
For the purposes of this study, we used the Brtl/+ mouse to investigate 
the effects of bisphosphonates in a model of OI.  Brtl/+ is heterozygous for a 
Gly349Cys substitution in col1a1, reproducing the genetic mutation found 
in a type IV OI child [85].  Brtl/+ mice have a moderately affected skeletal 
phenotype, with long bone deformities and fragility. In addition, Brtl/+ 
demonstrates post-pubertal adaptations to improve mechanical integrity with 
age, which is similar to the clinical observations of decreased fractures in 
human OI patients after skeletal maturity [15]. Moreover, we have shown in 
our earlier studies that the Brtl/+ mouse is more susceptible to microdamage 
accumulation during normal ambulation, and externally applied loading 










the effect of a 5 week bisphosphonate treatment protocol during the growing 
phase of the Brtl/+ mouse. We hypothesize that treatment with 
bisphosphonates will have an adverse effect on the mechanical integrity of 
bone which will be manifested through an increase in microdamage and a 
reduction in fracture toughness properties.  
 
3.2 Materials and Methods 
3.2.1 Murine Model 
A total of 38 male Brtl/+ and wild type WT (n= 19 each) mice were 
bred from our colony and used in this study. 8 week old male mice were 
assigned to 4 groups, which included bisphosphonate treated WT and Brtl/+ 
groups, as well as WT and Brtl/+ untreated groups with n=8/group. Brtl/+ 
mice have a mixed background of Sv129/CD-1/C57BL/6S and are bred by 
crossing heterozygous Brtl/+ with WT [38].  Animals were genotyped at 










DNA from mouse tails. Mice were allowed a regular diet of rodent chow and 
water ad libitum. All procedures used in this study were approved by the 
University Committee on Use and Care of Animals (UCUCA) at the 
University of Michigan. 
3.2.2 Bisphosphonate Treatment 
For this study, the effects of bisphosphonate treatment were compared 
between treated and untreated groups in Brtl/+ and WT mice. For the WT 
and Brtl/+ treated groups, the bisphosphonate Alendronate (Aln) (Sigma-
Aldrich) was injected subcutaneously at 0.219 mg/kg in PBS, once per week 
from 3 to 8 weeks of age. We chose this dosage to match earlier Alendronate 
treatment studies in the Brtl/+ mouse, to compare and contrast observations 
[58]. Earlier studies in the oim mouse demonstrated that this dosage was the 
lowest concentration required to increase mineralization and prevent 










3.2.3 In-Situ Strain Measurements 
The ulnar loading model [39] was used throughout this study to 
produce compressive loads and induce microdamage. This loading model 
has been shown to produce loads primarily within the ulna and not the 
radius, and has been shown to induce  microcrack formation within the ulna 
of rats [40]. The right forearms of mice were exposed to cyclic uniaxial 
compression loading across the olecranon and carpus process as described 
by others [40, 41]. Loading was done using a custom built servo-motor 
loader. Force-controlled, haversine, cyclic loading was performed at 1 Hz 
frequency while force and strain voltages were recorded using Labview 7.1 
software (National Instruments, U.S.A.). 
To measure strains in treated mice, 6 cadaver mice (n=3 Brtl/+ and 
n=3 WT) which were treated with Alendronate using the above mentioned 
treatment protocol, were used to record ulnar strains during cylic loading to 










microdamage in compression (estimated at 4000 micro strain) [40, 42].  
Earlier studies in the Brtl/+ mouse demonstrated that 4000 micro strain was 
sufficient to generate damage in both Brtl/+ and WT untreated bone [86]. 
The strain gauge technique was described in earlier studies [86]. Briefly, a 5 
mm incision was made at the mid-diaphysis of the right forearm and the 
bones were further prepared using prescribed techniques [43] and 
commercial reagents (Vishay Micro-Measurements, U.S.A.) for the 
placement of strain gauges. 100% ethanol followed by acetone was applied 
to the exposed ulna surface using a cotton tip applicator.  A catalyst 
(Catalyst-C) was then applied followed by a drop of adhesive (M-Bond 
200). Single element strain gauges (EA-06-015DJ-120, Vishay Micro-
Measurements, U.S.A.) were placed longitudinally as close to the lateral 
surface as possible of the ulna of both Brtl/+ and WT mice, near the mid-
diaphysis. It has been confirmed experimentally [41], as well as through 










is the region of highest compressive strain and deformation during axial 
ulnar loading.  
Cyclic loading was performed continuously, and several rounds of 
data were collected for each mouse and analyzed using linear regression in 
order to determine the load-strain relationship for both Brtl/+ and WT 
genotypes. From these regressions it was noted that the loads that induced 
approximately 4000 micro strain were 7.16 ± 0.71 N for the WT and 6.75 ± 
1.24 N for the Brtl/+ treated mice. Strain gauge data from our earlier studies 
showed that 4000 microstrain would be attained at 2.71 ± 0.35 N for Brtl/+ 
and 4.92 ± 0.04 N for the WT untreated mice [86]. 
Table 3-1 represents data collected from a small sample of untreated 
and treated animals using micro computed tomography (MicroCT). Using 
Euler’s Column Formula Eqn. (3-1), the theoretical critical buckling load 
was calculated assuming an effective length factor (K) of 1, to roughly 










load required to initiate critical buckling. The Imin value used was the lowest 
bending moment of inertia for each specimen, as it was assumed that failure 
would occur in the plane with the lowest bending moment of inertia. Using 
Young’s Modulus values from Kozloff et al. [15] and Uveges et al.[88] as 
references, (Brtl/+ untreated at 8 weeks old =862.44 MPa, WT untreated at 8 
weeks old=645.24 Mpa, Brtl/+ treatment for 6 weeks with Alendronate at 8 
weeks old =4319.4 Mpa and WT treatment for 6 weeks with Alendronate at 
8 weeks old=3306.8 MPa) the theoretical critical buckling loads were 
calculated. Despite the small number of animals analyzed, it does appear that 
the critical loads do in fact increase with treatment, which corresponds with 





















Pc = Critical buckling load 
E = Young’s Modulus (MPa) 
Imin = Minimum bending moment of inertia (mm
4) 
K = column effective length factor 
L = length of bone (mm) 
 
3.2.4 Cyclic Loading in Untreated Animals 
A total of 32 mice (n=16 Brtl/+ and n=16 WT) were used for cyclic 
loading. To induce microdamage, a similar loading protocol (1 Hz sinusoidal 
wave pattern) and data recording protocol was used as described for in-situ 
strain gauging, with the exception that force and actuator displacement were 
recorded using Labview 7.1 software. The contralateral forelimbs were not 
loaded and were used as controls to assess baseline levels of microdamage in 
the bone matrix. Each specimen was allowed a 5 minute (300 cycles) period 










compliance and thus isolate and account for the effects of the actuator 
displacement to that of solely bone matrix degradation [44]. This time also 
afforded the opportunity to gradually ramp up the force amplitudes for each 
forearm to produce the required range of strains, as necessitated by the 
intrinsic differences in bone size between animals.  Bones were then 
cyclically loaded for 30 minutes (1800 cycles) at force-controlled loads that 
produced approximately 4000 microstrain (µε) based on data collected in the 
in situ strain gauge experiments. Minimal compressive loads on the reversal 
phase of loading of approximately 2.45 N and 1.34 N for WT and Brtl/+ 
mice, respectively, were used to ensure that platens remained in contact with 
the bone during the unloading segment. Post hoc calculations showed that 
WT mice displayed compressive strains ranging between a minimum of 
approximately 100.5 µε during the unloading segment and  approximately 
3870 µε (approximately 5N) at maximum loading, whereas Brtl/+ exhibited 










loading segments, respectively. The displacement of the ulna during cyclic 
loading was recorded for each bone using a linear variable differential 
transformer (LVDT). Loss of stiffness for each bone was determined using 
Eqn. (3-2), which was previously used by Bentolila et al. [40] as a surrogate 
for effective stiffness loss.  
 
Equation 3-2: 





                                                                           
 
where Lo is the initial length of bone and L is the final length of the bone. 
The initial length was always measured at the end of the dynamic pre-
conditioning period (300 cycles) while L was measured when loading was 
complete. Both Lo and L were measured using the calibrated external LVDT 










3.2.5 Cyclic Loading in Treated Animals 
Treated animals were loaded using the same protocol as untreated 
specimens and their stiffness loss was calculated similarly. However, during 
the initial stages of testing these animals, some WT (n=2) and Brtl/+ (n=2) 
animals underwent premature fracture of the ulnas during testing. A 
representative image displaying where most fractures occurred in treated 
specimens is shown in Figure 3-1. These animals were dropped from the 
study and as a result of this observation, subsequent treated animals were 
loaded to a reduced load that induced approximately 3000 µε in order to 
ensure successful completion of the 35 minute loading protocol. Minimal 
compressive loads on the reversal phase of loading of approximately 2.43 N 
and 2.24 N for WT and Brtl/+ mice, respectively, were used to ensure that 
platens remained in contact with the bone during the unloading segment. 
Post hoc calculations showed that WT treated mice displayed compressive 










unloading segment and approximately 2800.6 µε (approximately 5N) at 
maximum loading, whereas treated Brtl/+ specimens exhibited strains 
ranging from 63.6 and 2743.4 µε (approximately 4.5N) during unloading 
and loading segments, respectively. Under these revised testing protocols, 
treated specimens were able to complete the full 35 minute loading protocol 
as their untreated counterparts. 
3.2.6 Confocal Microscopy Parameters 
After euthanasia both loaded and unloaded forelimbs were excised 
and fixed in 10% neutral buffered formaldehyde. Bones were then stained 
with 1% basic fuchsin using an established protocol [45] and rinsed in 100% 
ethanol. Samples were subsequently embedded undecalcified in poly methyl 
methacrylate (PMMA) for histology. Using a Buehler Isomet diamond-blade 
saw, 400 µm sections were then cut transverse to the longitudinal axis of the 
ulna. These sections were mounted on a plastic microscope slide and 










viewed using a 2-Photon Leica confocal inverted microscope system (SP5X 
Zeiss Confocal Microscope, Carl Zeiss MicroImaging, Inc., Thornwood, 
NY, U.S.A.), to identify bone areas stained with basic fuchsin. A 40X oil 
immersion objective was used to capture images. In order to image the basic 
fuchsin, an excitation of 543nm was used, with an emission range of 553-
613nm.  
3.2.7 Microdamage Quantification 
Images were taken for the entire 100 µm thick cortical region and 
subsequently analyzed using the Leica LAS AF Image Browser (Version 
2.6.0 Build 7266, Leica Microsystems CMS, Inc.) to quantify linear 
microdamage within the cortical region. Cracks that were positively labeled 
with basic fuchsin dye were deemed as damage-induced during loading. 
Diffuse damage was not assessed in this study. The following parameters 
were measured throughout the entire cortical bone region of each section: 










numerical density (Cr.Dn., #/mm3) and microcrack surface density 
(Cr.S.Dn., mm/mm3). 
3.2.8 Fracture Toughness 
To correlate microdamage with fracture toughness, right femurs from 
each mouse were prepared and tested according to techniques established by 
Ritchie [46]. This technique utilizes linear elastic fracture mechanics 
(LEFM) principles and a self-induced starter notch to measure the bone’s 
resistance to fracture (fracture toughness). For regular mechanical testing of 
engineering materials, ASTM standards require that a sharp starter notch be 
the initiation point of fracture [47]. This starter notch is typically induced by 
a fatigue loading technique; however, due to the small geometry of mouse 
bones, this procedure is not optimum. Studies have shown that accurate 
fracture toughness data can be attained from razor sharpened micronotches 
[48] and this technique has been deployed for small animal studies [46] 










measure of the bone’s inherent fracture toughness, without the viscoelastic 
influence of soft tissue.  
The right femora from each group were harvested, cleaned of soft 
tissue, and stored frozen at -20°C in gauze soaked in Lactated Ringer’s 
Solution (LRS) until testing. Bones were machine-notched through the 
posterior cortex at the mid-shaft using a micro milling device with a cutting 
radius of 0.01 inches. Notches were then sharpened using a custom rigged 
mounted razor blade, pasted with 1 µm diamond polish (Struers). Bone 
diameters were measured with electronic calipers and notch depths were 
made using a micro mill to approximately 1/3 of the bone diameter[86].  
This notching procedure typically produces a reproducible sharpened notch 
root radius of approximately 10 µm [46, 48] .  
In preparation for three-point mechanical bend testing, the femoral 
heads were removed, while the condyles were left intact. This was done to 










thawed in LRS soaked gauze at room temperature to preserve moisture 
content until they were ready for testing. Specimens were loaded to failure in 
three-point bending at 0.001 mm/s using a servohydraulic testing machine 
equipped with a 220N load cell (858 MiniBionixII Material Test System; 
MTS Systems Corporation, Eden Prairie, MN, USA) in accordance to 
ASTM standards [47, 49] and other established protocol [46]. During three-
point bending, the specimens were placed such that the posterior surface was 
in tension and the anterior surface was in compression with the top loading 
point oriented directly above the notch on the anterior surface.  A span 
length of 4.5 mm was used in testing. Load and displacement values were 
recorded throughout the experiment using integrated Material Test System 
data acquisition software (858 MiniBionixII Material Test System; MTS 
Systems Corporation, Eden Prairie, MN, USA).   
After mechanical testing, fractured bone specimens were fixed in 70% 










tissue with 2% potassium hydroxide for 12 hours. The specimens were 
dehydrated by immersion in a graded series of alcohols (50%, 70%, 95% 
and 100%) and coated with carbon [37].  Specimens were imaged by SEM 
to determine the transition from stable to unstable crack growth (Figure 2-
4).  Fracture toughness, Kc, was measured using solutions for 
circumferential through-wall cracks established for cylindrical pipes [46, 50, 
51]. Both the maximum load and the crack instability techniques were used 
to determine fracture toughness values [46]. All measurements used in the 
LEFM calculations, such as specimen width and thickness, were taken from 
SEM images of fracture sites using the public domain software ImageJ 
(National Institutes of Health).  
All measurements of thickness and radii were measured on the 
fracture surface of each specimen i.e. the non-notched surface as previously 
instructed by Ritchie [46]. Cortical thickness was taken as an average 










the fracture surface. The centroid for each specimen was determined by 
drawing a line parallel to the notch that was half the bone’s diameter. This 
line represented the major axis. Another axis that was rotated 90 degrees to 
the first was also placed at half the bone diameter. This line represented the 
minor axis. The intersection of these perpendicular lines represented the 
centroid of the bone (Figure 2-5).  In determining the stable to unstable 
transition region, the SEM was used in backscatter mode. The difference in 
morphology was used to determine the transition. The stable region is 
typically described as having a darker appearance with linear groves, 
whereas the unstable region has a more spongy appearance. Half-crack 
angles (2θ) were determined by measuring the included angle (maximum 
load technique) which is formed from the centroid to the notched surface, 
and with the excluded angle (instability technique) which is formed from the 











Effect between loaded and unloaded limbs within each group (WT 
treated, WT untreated, Brtl/+ untreated and Brtl/+ treated) on percent 
stiffness loss, crack numerical density, and crack surface density, were 
compared using a paired Student’s t-test (Microsoft Excel 2010). Effects 
between treatment groups on the same limbs (loaded or unloaded) within the 
same genotype were performed using unpaired t-test (Microsoft Excel 
2010). Effects of treatment within the same genotype on fracture toughness 
values calculated using either the maximum load or instability technique  
were compared using unpaired t-tests. The overall effect of genotype, 
loading or treatment was compared using linear mixed models with repeated 
measures within the subject (IBM SPSS Statistics v. 20) In all tests, 












3.3.1 WT and Brtl/+ treated specimens underwent premature fracture 
During the early stages of loading treated specimens at loads required 
to induce 4000 µɛ, 4 animals (2 WT and 2 Brtl/+) suffered premature 
fracture during loading at the metaphyseal regions in both ulna and radius 
(Figure 3-1). Figure 3-5 shows the bone architecture at the typical regions 
of fracture. The radius fracture occurred in predominantly cortical bone 
while the ulnar fracture occurred in the trabecular region at the proximal 
metaphyseal region. This observation could possibly indicate weaker 
trabeculae in treated specimens as opposed to untreated specimens. As a 
consequence of this observation, loads were adjusted to produce 
approximately 3000 µɛ in order for treated specimens to complete the 35 
minute loading protocol as their untreated counterparts. Upon this 










3.3.2 Brtl/+ ulnae demonstrate lower stiffness loss during loading 
Whole bone loss of stiffness for each forearm was measured via 
LVDT during cyclic loading according to Equation (2-1).  While Brtl/+ and 
WT untreated ulnae were loaded with matching surface strains (~4000 µɛ), 
Brtl/+ demonstrated a significantly lower percentage stiffness loss compared 
to WT (5.65 ± 1.15% and 9.41 ± 1.41% respectively; p<0.05) over the 35 
minute load period. Interestingly, despite both Brtl/+ and WT treated 
specimens being loaded to similar (~3000 µɛ), yet lower surface strains than 
their untreated counterparts they both attained similar stiffness losses as their 
untreated counterparts at the end of the loading protocol (Brtl/+ treated = 
6.02 ± 2.78% vs. WT treated = 9.19 ± 2.68%; p<0.05) (Figure 3-2). When 
treated limbs were pooled together and compared to untreated groups, no 










3.3.3 Unloaded and loaded Brtl/+ ulnae have more microdamage than WT 
counterparts 
Both unloaded treated and untreated control limbs from Brtl/+ 
demonstrate significantly increased linear microcrack numerical density 
(85.0% (p=0.040) and 124.9% (p=0.044) respectively) and microcrack 
surface density (72.5% (p=0.032) and 81.8% (p=0.053)) compared to their 
WT counterparts (Figure 3-3 A,B).  Similarly, both loaded treated and 
untreated limbs from Brtl/+ demonstrate significantly increased linear 
microcrack numerical density (75.2% (p=0.011) and 103.9% (p=0.015) 
respectively) and microcrack surface density (75.1% (p=0.052) and 136.9% 
(p=0.003)) compared to their WT counterparts (Figure 3-3 A,B).   
3.3.4 Cyclic loading resulted in increased levels of damage 
In general, loaded limbs for both WT and Brtl/+ had significantly 
more microdamage than their unloaded contralateral limbs in both treated 










exception of the WT treated group, which saw a trend towards an increase in 
both crack numerical density and crack surface density following cyclic 
loading, but did not achieve significance (p=0.076 and 0.105 respectively). 
Despite this, cyclic loading globally resulted in an increase in microdamage 
when compared to unloaded limbs in both crack surface density and crack 
numerical density (p<0.05 for both measures) 
3.3.5 5 weeks of Alendronate treatment did not impact microdamage 
content in unloaded limbs 
There were no significant differences observed in damage content in 
unloaded limbs for either genotype when comparing treated to untreated 
groups. Similar observations were seen in both crack numerical and crack 










3.3.6 Despite loading to a lower surface strain, treated limbs attained 
similar levels of microdamage 
There were no significant differences observed between treated loaded 
limbs and untreated loaded limbs. This occurred despite the fact that treated 
limbs were loaded approximately 1000 µɛ less than their untreated 
counterparts. Similar trends were seen in both crack numerical and surface 
density calculations (Figure 3-3 A,B). This observation suggests that 
loading at 3000 µɛ in treated specimens produces as much damage content 
as loading at 4000 µɛ  in untreated specimens. When pooling all treated 
limbs and comparing them to untreated limbs, 5 weeks of Alendronate 
treatment did not result in an increase in microdamage content (p=0.134 for 
crack numerical density and p=0.680 for crack surface density). 
3.3.7 Brtl/+ femora display a reduced fracture toughness compared to WT 
Using the maximum load technique, which assesses fracture 










encountered during three-point bending, WT untreated femora displayed 
average Kc values of 3.94 Mpa√m whereas Brtl/+ untreated specimens had 
Kc values of 3.17 Mpa√m (p=0.062) (Figure 3-4). The instability technique 
relies on identification of the transition between unstable and stable crack 
growth, and showed a more sensitive difference in Kc values between 
genotypes (WT 3.96 Mpa√m; Brtl/+ 2.79Mpa√m) (p=0.014) (Figure 3-4).  
 Similar trends were seen when comparing treated to untreated 
specimens in WT and Brtl/+ specimens. Brtl/+ treated demonstrated a 
significant decrease in maximum load fracture toughness when compared to 
their WT treated counterparts (WT = 3.43 Mpa√m; Brtl/+ = 2.66Mpa√m)  
(p=0.025) whereas instability fracture toughness values showed a trend 
towards a decrease in Brtl/+ treated femora when compared to WT treated 










3.3.8 Bisphosphonate treatment results in a trend towards reduced fracture 
toughness in both Brtl/+ and WT 
When comparing treated to untreated groups in both Brtl/+ and WT, 
we observe a general trend of reduced fracture toughness. WT treated was 
12.9% lower (p=0.168) than WT untreated maximum load fracture 
toughness, while Brtl/+ treated was 16.0% (p=0.155) lower than Brtl/+ 
untreated.  
Similar trends were seen when analyzing the instability fracture 
toughness values. WT treated was 21% (p=0.03) lower than WT untreated 
fracture toughness, while Brtl/+ treated was 11.8% lower than Brtl/+ 
untreated, however this difference was not statistically significant (p=0.469) 
(Figure 3-4).  
After combining all treated limbs and comparing them to untreated 










fracture toughness (p=0.061 for maximum load fracture toughness and 
p=0.063 for instability fracture toughness) 
3.3.9 Fracture toughness correlations with microdamage 
In order to determine if there were any correlations between crack 
numerical density and crack surface density and fracture toughness, loaded 
and unloaded specimens were pooled together into separate linear regression 
models (Figures 3-6 and 3-7).  In loaded treated limbs, Brtl/+ and WT 
showed negative correlations in crack numerical density (CND) versus 
instability fracture toughness (R=-0.66 and p=0.005), crack surface density 
(CSD) versus maximum load fracture toughness (R=-0.472 and p=0.065), 
CSD versus instability fracture toughness (R=-0.409 and p=0.116), as well 
as CND versus maximum load fracture toughness (R=-0.610 and p=0.012) 
(Figures 3-6 and 3-7) 
It appears that unloaded limbs are weakly correlated with fracture 










load fracture toughness showed any strong correlations with either CND or 
CSD (Figures 3-6 and 3-7)  
 
3.4 Discussion 
Bisphosphonates have been a popular treatment option for patients 
suffering from low bone mass diseases. They have been used in the 
osteoporosis community for over 40 years and more recently in the treatment 
of osteogenesis imperfecta patients. While there has been marked 
improvement in vertebral strength and structure, a growing concern with 
bisphosphonates are reports in animal models that they may adversely 
impact mechanical integrity of bone by reducing toughness and by 
preventing the repair of microdamage. This study utilized the Brtl/+ mouse 
as a model to investigate the impact of a 5 week (3-8 weeks of age) 










and the resulting fracture toughness properties of bone formed with an OI-
causing mutation.  
Both treated and untreated Brtl/+ ulnae subject to normal cage activity 
demonstrated significantly higher levels of microdamage than their WT 
counterparts. Extended bisphosphonate treatment did not seem to impact the 
levels of microdamage in unloaded limbs in either Brtl/+ or WT specimens.  
However, loading produced equivalent levels of microdamage and stiffness 
loss in treated animals compared to untreated animals despite loading to 
25% reduced surface strain. This decrease in durability is supported by a 
trending decrease in femoral fracture toughness properties of both WT and 
Brtl/+ treated animals compared to untreated mice.    
In mechanics, fracture toughness serves as an inherent material 
property that measures a material’s ability to resist damage. In this study, 
there were moderate reductions in fracture toughness observed following 










fracture toughness showed a significant decrease in WT treated femurs when 
compared to WT untreated femurs. This decrease in fracture toughness is 
supported by other studies which demonstrate a decrease in whole bone 
toughness with extended bisphosphonate treatment [80, 82, 89, 90]. 
Toughness or work to failure, is a common mechanical parameter measured 
in the mechanical testing of bone that can somewhat serve as a surrogate 
indicator of a material’s ability to resist fracture. The decreased toughness or 
work to failure associated with bisphosphonate treatment suggests that 
bisphosphonate treatment may compromise the bone’s ability to prevent the 
onset of critical failure microcracking. 
Our moderate differences in fracture toughness could have been 
caused by a structural change in the material that could lead to a reduction in 
the material’s ability to resist crack initiation or could result from some other 
morphological change such as altered collagen crosslinking, increased 










treatment does not appear to affect Brtl/+ or WT’s ability to resist crack 
initiation as crack numerical density (the number of cracks) is similar in both 
unloaded limbs of treated and untreated Brtl/+ and WT specimens. However 
this does not dismiss the possibility of macroscopic morphological changes.  
Bisphosphonates have been shown to increase the levels of non-enzymatic 
cross-linking (pentosidine), as well as altering the ratio of enzymatic cross-
links (pyridinoline/deoxypridinoline), and increasing collagen isomerization 
(tissue age) which could explain our observed trends in reduced fracture 
toughness [91, 92]. 
When looking at fracture toughness correlations, we generally saw 
negative correlations in loaded limbs regardless of whether they were treated 
or not when comparing damage metrics (CND and CSD) to fracture 
toughness values. These correlations were weaker in unloaded limbs. It 
appears that loaded limbs have the more profound correlations, quite 










loaded limbs as opposed to unloaded limbs. Despite the general observation 
that microdamage increases as fracture toughness decreases in both loaded 
and unloaded limbs, it appears that fracture toughness variations have more 
profound effects when limbs are loaded at high strains as opposed to 
undergoing ambulatory loading.  
In our previous study involving the Brtl/+ mouse and microdamage, 
we demonstrated similar results in untreated mice as the current study, 
including decreased loss of stiffness in Brtl/+ as well as increased levels of 
microdamage in loaded limbs [86].  In the current study, we noted an 
increase in load required to induce 4000 µɛ in both Brtl/+ and WT treated 
specimens when compared to their untreated counterparts. However, the 
technicalities involved when collecting strain gauge data must be noted. 
Several rounds of cylic loading strain-load data were collected and curves of 
best fit for each were calculated. It was from these curves that strains were 










experimentally we were able to attain loads of 4000 µɛ in both treated Brtl/+ 
and WT ulnas, these loads were not maintainable for the course of 2100 
cycles. This issue was not observed in untreated specimens.  
Both crack numerical density (CND) and crack surface density (CSD) 
showed significant increases in loaded limbs when compared to their 
unloaded limbs in both treated and untreated groups. The only exception to 
this trend was the WT treated group, which showed a trend towards an 
increase in CND (p=0.076) and CSD (p=0.105). Additionally, we observed 
both WT and Brtl/+ specimens suffering whole bone failure when loaded at 
4000 µɛ (Figure 3-1). This observation promoted the reduction to 3000 µɛ 
in surface strain used for the treated specimens which enabled the treated 
specimens to complete the same number of cycles as their untreated 
counterparts. A similar observation was seen in oim mice that demonstrated 
low work to failure and required fewer cycles to generate equivalent 










any pharmacological treatment. Both of these observations combined with 
the above mentioned matching stiffness loss, suggest that the treated bone 
has a decreased ability to resist the onset of critical microcracking and 
perhaps decreased whole bone durability in repetitive high strain loading 
conditions. Again, we suspect that altered collagen cross-linking may play a 
role in these observations. Increased cross-linking (measured through 
pentosidine concentrations) has been shown to reduce ultimate strain [93] 
and the amount of post-yield deformation [94-96], which are both 
characteristics of a brittle material. It has been proposed that the increased 
cross-linking through non-enzymatic processes that result from 
bisphosphonate treatment results in a more brittle tissue through either the 
prevention of stress relaxation that normally occurs with crack initiation or 
by allowing generated cracks to propagate more easily [97, 98].  Thus, we 
suspect the high strains exerted during loading in concert with the 










have contributed to both the observed premature fractures at 4000 µɛ as well 
as the increased levels of microdamage despite loading at a decreased 
surface strain. 
Another potential area in which bisphosphonates could adversely the 
whole bone fatigue durability is through the retention of calcified cartilage. 
This phenomenon is seen clinically as sclerotic bands, which are typically 
located in the metaphyseal regions of bones in bisphosphonate treated 
patients [69, 99-101]. These sclerotic bands tend to occur during the fast 
paced growth phase of patients, and the distance between the bands are 
considered times during which normal osteoclastic activity has resumed[99]. 
Sclerotic bands have been associated with timing of bisphosphonate 
treatment, and correspond with times of decreased osteoclastic activity [102, 
103]. Sclerotic bands have been speculated to result in decreased mechanical 
integrity [104]. Clinical observations suggest that areas in the metaphysis 










undergo fractures [105].  The occurrence of retained mineralized cartilage is 
not unique to humans, but has also been observed in murine models treated 
with bisphosphonates [84, 87, 106, 107]. Work done by Uveges et al. 
showed the retention of calcified cartilage in the femora of Alendronate 
treated mice [58]. Incidentally, this metaphyseal area where sclerotic bands 
are prominent corresponds with the region of premature forearm fractures 
observed in this study. It is possible that the reason for our observations of 
fractures at this site could be due to the presence of mineralized cartilage 
that could serve as a weak spot for the global structural integrity of the bone. 
In unloaded limbs, there was no difference in microdamage content in 
either treated or untreated limbs. We suspect that the low strains exerted 
during regular ambulation (~1000 µɛ) [41, 108, 109] are not large enough to 
generate significant increases in microdamage content between treated and 
untreated limbs. If increased damage content is to be taken as an indicator of 










no significant changes in damage content in treated versus untreated loaded 
limbs would support the clinical observations of no significant improvement 
in long bone fracture rates observed in bisphosphonate treated patients  [69, 
75, 77, 78, 110]. The observations of this study can be further extended to 
the clinical postulations that extended bisphosphonate therapy is associated 
with atypical, low-energy subtrochanteric femoral fractures observed in 
osteoporotic patients undergoing treatment [29, 30]. The results of the 
present study support the notion that either slightly reduced fracture 
toughness, or the high strains seen at the hip [111], could be a contributing 
factor toward these subtrochanteric femoral fractures. Furthermore, these 
observations could also have strong implications for fracture prone 
osteogenesis imperfecta (OI) patients on bisphosphonates who may be more 
susceptible to microdamage accumulation as suggested by animal models 










susceptible to critical bone failure, any treatment modalities that potentially 
affect damage repair needs to be carefully assessed.    
Bisphosphonates are used clinically to improve bone integrity by 
increasing bone mass, and their efficacy in improving vertebral bone mineral 
density and geometry as well as decreasing vertebral fracture rates have been 
well documented in the osteoporosis community [112-114] . However, there 
have been reports in several animal models that indicate an increase in 
skeletal microdamage after extended treatment [79-81], which subsequently 
leads to a decrease in mechanical integrity of the bone [80-82]. It is 
proposed that the inhibition of bone remodeling by bisphosphonates could 
be a key factor that results in the accumulation of microdamage over time 
[115, 116]. The relatively short term treatment utilized in this study may 
further explain the lack of differences observed in microdamage in unloaded 
limbs. It is possible that if extended further, more significant fracture 










Brtl/+ specimens. Indeed, Uveges et al. saw more significant mechanical 
differences at 12 weeks of Alendronate treatment than at 6 weeks of 
treatment, including decreased predicted strength and modulus [58]. While 
we are not directly implicating Alendronate with our observations, it must be 
noted that Alendronate is a highly potent bisphosphonate that has been 
implicated in reduced material properties [117, 118],  increased levels of 
microdamage [119], as well as increased non-enzymatic glycations[120]. 
Further studies investigating the role of other bisphosphonates on fracture 
toughness and microdamage in the Brtl/+ mouse would prove useful.  
In conclusion, this study shows that 5 weeks of bisphosphonate 
treatment in the Brtl/+ mouse model for osteogenesis imperfecta results in a 
moderate trend towards a decrease in fracture toughness and no significant 
differences in microdamage levels in unloaded limbs. Additionally, less 
force is required to induce similar levels of stiffness loss as well as similar 










suggest that bisphosphonates may not be detrimental at lower strains such as 
those exhibited in normal ambulation, but may result in compromised 
mechanical integrity at higher strains. Longer treatment with bisphosphonate 
is needed to determine if these differences are more pronounced. The 
findings of this study suggest that the efficacy of bisphosphonates is still 













Figure 3-1: Typical fracture position seen in treated forearm failure 
A Nano-CT image demonstrating the typical regions of observed failure during cyclic 











Figure 3-2: % stiffness loss in treated and untreated loaded specimens 
Percent stiffness loss between WT and Brtl/+ in treated and untreated specimens. Despite 
loading to different surface strains based on treatment, similar stiffness losses were 
reached in both WT and Brtl/+ specimens. 












Figure 3-3: Crack surface and numerical density comparisons 
Chart representing the degree of microdamage in treated and untreated limbs as measured 
by crack surface density (A) and crack numerical density (B). * p<0.05 between treated 
WT and treated Brtl/+; # p<0.05 between untreated WT and untreated Brtl/+. β: p<0.05 
between loaded and unloaded limbs in that treatment group. $: p=0.0515 between Brtl 
treated loaded limbs and WT treated loaded limbs. 











Figure 3-4: Fracture toughness comparisons 
Figure representing the fracture toughness as represented by instability fracture 
toughness and maximum load fracture toughness. *: p<0.05 WT treated vs. Brt/+ 












Figure 3-5: Morphological images of fracture sites 
Figure shows the bone structure in the regions where fracture typically occurred. 
The radial fracture occurred in the cortical region of the proximal metaphyseal area. The 












Figure 3-6: Crack numerical density vs. fracture toughness correlations  
Correlations between instability fracture toughness values and crack numerical 
density in pooled untreated (A) and pooled treated (C) animals as well as maximum load 
fracture toughness and crack numerical density in pooled untreated (B) and pooled 
treated (D) animals. Fracture toughness was generally negatively correlated with loaded 










however, the slopes were significantly different in the relationship governing instability 
Kc and CND (p=0.009) in treated animals (figure C). 
 
 
Figure 3-7: Crack surface density vs. fracture toughness correlations 
Correlations between instability fracture toughness values and crack surface 
density in pooled untreated (A) and pooled treated (C) animals as well as maximum load 
fracture toughness and crack numerical density in pooled untreated (B) and pooled 
treated (D) animals. Fracture toughness was generally negatively correlated with loaded 
and unloaded CND. There were no significant differences in the loaded or unloaded 
slopes in figures B or D, however, the slopes were approaching a significance in different 










(figure A) as well as that governing instability Kc and CSD (p=0.103) in treated animals 
(figure C).  
 













Visualization of Bisphosphonate Binding to Bone Microcracks, 
Surrounding Osteocyte Lacunae, and Osteocyte Apoptosis 
Spatial Distribution Using Near-Infrared Optical Imaging  
4.1 Introduction 
Bisphosphonates are a potent anti-resorptive drug commonly used to treat 
diseases of low bone mass or high bone turnover such as osteoporosis [67], 
Paget’s disease [68], and osteogenesis imperfecta [121].  These drugs reduce 
bone turnover through the inhibition of osteoclast activity, thereby 
increasing bone mass and reducing bone fragility.  Despite strong clinical 
findings supporting the use of bisphosphonates in treating bone fragility, 










bisphosphonates on the inhibition of targeted repair of skeletal 
microdamage.  Extended bisphosphonate use has been correlated with 
observations of increased microdamage accumulation in animal models [24-
27], and this may have detrimental effects on bone toughness and increased 
fragility with long-term use [24-26, 28].  Furthermore, while a causative 
relationship has not been proven, the association between bisphosphonate 
therapy and atypical, low-energy subtrochanteric femoral fractures has led to 
suggestions that long-term bisphosphonate use may indeed have a negative 
clinical indication in a sub-population of patients undergoing therapy [29, 
30].   
Several mechanisms governing the accumulation of bone microdamage 
under extended bisphosphonate therapy have been proposed.  Reduced bone 
remodeling and the associated effects of increased bone age may lead to 
alterations in both collagen and mineral which could predispose the bone to 










with accumulation of altered collagen cross-linking [122-124], increased 
tissue mineralization [125, 126], and reduced microstructural interfaces 
[127, 128], all of which may make the skeleton more prone to the generation 
or propagation of tissue damage.  Alternatively, direct interference with 
osteocyte apoptosis induction [129-132], apoptotic activation of osteoclast-
stimulating pathways [133, 134], or the targeting and repair of damage by 
osteoclasts themselves [40] will likely lead to the accumulation of damage in 
the skeleton.  Bisphosphonates not only inhibit osteoclast activity directly, 
but also inhibit osteocyte apoptosis in the presence [27, 135] and absence 
[132, 136, 137]  of microdamage, thus potentially modulating microdamage 
repair at multiple levels.  
A direct localization of bisphosphonates at the site of microdamage 
has not yet been visualized.  Vascular perfusion studies have shown that 
fluorescent contrast agents can pool at microcracks and nearby surrounding 










are permissible for local bisphosphonate binding.  If this were the case, this 
would suggest a potential for both direct and indirect effects of 
bisphosphonates on modulating targeted microdamage repair.  Recently, we 
have demonstrated the use of bisphosphonates labeled with near-infrared 
fluorophores for the local detection and quantification of bisphosphonates in 
vivo, ex vivo, and in histologic sections [140, 141].  The purpose of this 
study is to visualize local bisphosphonate binding to bone microdamage and 
surrounding osteocyte lacunae as well as to investigate the impact of 
extended bisphosphonate treatment on osteocyte apoptosis in a model of 
bone microdamage.  In particular, we have chosen to apply this in normal 
bone as well as bone that is susceptible to the generation and accumulation 
of bone microdamage via a collagen mutation resulting in a brittle, 
osteogenesis imperfecta-like phenotype [15, 86].  We hypothesize that 
microcracks and their surrounding osteocyte lacunae are particularly prone 










extended treatment with bisphosphonates will lead to a suppression of 
osteocyte apoptosis around areas of microdamage.  We further seek to 
determine whether the alterations in collagen composition characteristic of 
osteogenesis imperfecta can alter the distribution of drug to microcracks and 
their surrounding osteocytes.  If successful, these findings may have 
implications for understanding the association of bisphosphonates and 
microdamage with the emerging findings of atypical fractures in 
osteoporotic patients treated with bisphosphonates, as well as have potential 
implications for OI patients who may be particularly susceptible to the 












4.2 Materials and Methods 
4.2.1 Murine Models 
A total of 17 Brtl/+ and 20 WT mice were used for this study. Brtl/+ 
mice have a mixed background of Sv129/CD-1/C57BL/6S and are bred by 
crossing heterozygous Brtl/+ with WT [38]. All procedures used in this 
study were approved by the University Committee on Use and Care of 
Animals (UCUCA) at the University of Michigan. Three additional Brtl/+ 
mice were used as staining controls to determine threshold levels for 
imaging. 
4.2.2 Bisphosphonate Treatment 
For the WT and Brtl/+ treated groups investigating the effects of 
bisphosphonate treatment on osteocyte apoptosis, the bisphosphonate 
Alendronate (Aln) was injected subcutaneously at 0.219 mg/kg in PBS, once 










Alendronate treatment studies in the Brtl/+ mouse [58]. Earlier studies in the 
oim mouse demonstrated that this dosage was the lowest concentration 
required to increase mineralization and prevent resorption [87].  Untreated 
mice received no injections at any time point.    
4.2.3 Cyclic Loading 
Mouse ulnae were loaded according to a previously established 
protocol  [86] with the aim of generating microdamage. Earlier 
measurements were taken to attain the strains of treated and untreated 
specimens. Treated specimens were loaded to approximately 3000 
microstrain on the mid-diaphyseal ulna, while untreated specimens were 
loaded to approximately 4000 microstrain. At 8 weeks of age, animals were 
anesthetized with 2% isoflurane and prepared for loading. The right 
forearms of Brtl/+ and WT mice were cyclically loaded across the olecranon 
and carpus [40, 41] at 1 Hz for 1800 cycles (30 minutes) following a 300 










minimum compressive load of approximately 400-500 micro strain was 
maintained to preserve limb orientation within the loading device.  
4.2.4 Fluorescent Bisphosphonate (FRFP) Administration 
Upon the conclusion of loading, a cohort of mice untreated with 
bisphosphonate (n=6 WT and n=6 Brtl/+) were administered a single dose of 
the far-red fluorescent pamidronate (FRFP) Osteosense 680 (Perkin Elmer, 
U.S.A.) while still under general anesthesia. The administered dosage was 
4nmols of FRFP per 20 grams body mass buffered in PBS in a total injection 
volume of 150 µL via tail vein injection. Mice were then allowed to recover 
and resume normal ambulation. Food and water was administered ad 
libitum. Mice were then subsequently euthanized 24 hours after loading.  
4.2.5 In-Vivo Apoptosis Marker (AV750) Administration 
In order to measure apoptosis levels in bones, the in-vivo apoptosis 










a cohort of treated (n=6 WT and n=4 Brtl/+) and untreated (n=8 WT and n= 
7 Brtl/+) mice immediately after loading was completed while under 
anesthesia. These mice were a separate cohort than the mice injected with 
FRFP in the previous section. AV750 solution was pre-mixed by 
PerkinElmer, and was administered unadulterated using the recommended 
dosage of 100 µL per mouse. AV750 is supplied in 1000 µL of 25 mM 
Hepes/NaOH, 140 mM NaCl at a molecular weight of 35kg/mol-1. Mice 
were then allowed to recover and ambulate but were euthanized 2 hours later 
using CO2 based on manufacturer suggested protocols. 
4.2.6 Verification of In-Vivo Apoptosis Marker 
In order to ensure that the in-vivo apoptosis marker AV750 is in fact 
staining apoptotic regions, an adult mouse was injected with AV750 and 
then euthanized 2 hours later. Briefly, tibias were excised, fixed in 10% 
NBF, dehydrated in a graded series of alcohol and subsequently embedded 










Buehler Isomet diamond-blade saw, 400 µm sections were then cut parallel 
to the longitudinal axis of the tibia. These sections were mounted on a 
plastic microscope slide and polished to a final thickness of 100 µm.  
Sections were cover slipped and viewed using a 2-Photon Leica confocal 
inverted microscope system (SP5X Zeiss Confocal Microscope, Carl Zeiss 
MicroImaging, Inc., Thornwood, NY, U.S.A.), at 40X objective to identify 
hypertrophic chondrocytes at the proximal tibial growth plate. The AV750 
was imaged using an excitation laser of 670nm with an emission range of 
700-790 nm.  (Figure 4-1 G-I). Control images were also taken to ensure 
limited auto fluorescence and signal bleed through (Figure 4-1 J-L). 
Annexin-Vivo 750 signals at the tibial growth plate region were 
compared against tibial growth plate sections stained with a terminal 
deoxynucleotidyl transferase-dUTP nick end labeling (TUNEL) assay, 
which is the gold-standard for in situ apoptosis signaling and imaging 










in 10% NBF, decalcified and embedded in paraffin. Longitudinal 7 µm 
sections of the tibia were subsequently taken using a Reichert-Jung 
microtome. Sections were then de-parrafinized and stained with 
TUNEL/Hoechst using the Click-iT TUNEL Alexa Fluor Imaging Assay 
(Molecular Probes, Invitrogen Detection Technologies, Eugene, OR U.S.A). 
Specimens were then imaged using the above mentioned 2-Photon Leica 
confocal using Invitrogen’s recommended excitation of 590nm and emission 
of 670nm. Control images were taken to ensure limited auto fluorescence 
and signal bleed through (Figure 4-1 D-F) 
    
4.2.7 FRFP Imaging Protocol 
Loaded forelimbs were excised and stained with 1% basic fuchsin 
using an established protocol [45] and rinsed in 100% ethanol. Samples were 
subsequently embedded undecalcified in poly methyl methacrylate (PMMA) 










were then cut transverse to the longitudinal axis of the ulna. These sections 
were mounted on a plastic microscope slide and polished to a final thickness 
of 100 µm.  Sections were cover slipped and viewed using a 2-Photon Leica 
confocal inverted microscope system (SP5X Zeiss Confocal Microscope, 
Carl Zeiss MicroImaging, Inc., Thornwood, NY, U.S.A.), to identify bone 
areas stained with FRFP and basic fuchsin. A 40X oil immersion objective 
was used in this study. To determine an approximation of the excitation and 
emission curves for both dyes, lambda scans were performed on cortical 
control specimens using the white light laser of the 2-Photon microscope. 
The first scan was performed on a specimen stained with basic fuchsin only, 
whilst the second scan was done on a FRFP stained sample. Excitation scans 
were performed in increments of 5nm between 480 nm and 670 nm whilst 
emission scans were performed in increments of 5nm between the range of 
500 nm and 800 nm. In order to image the basic fuchsin, an excitation of 










FRFP was imaged using an excitation laser of 670nm with an emission 
range of 700-750 nm (Figure 4-3). These parameters were held constant for 
all images and ensured limited signal bleed through to the opposing 
channels.  
4.2.8 FRFP Image Analysis and Staining Thresholds 
All images were scored using the pixel intensity tool provided by the 
public domain software ImageJ (National Institutes of Health). In order to 
validate the detected FRFP signal, a basic fuchsin control specimen was 
imaged under FRFP excitation and emission to determine the degree of 
crosstalk of basic fuchsin dye into the FRFP channel. It was determined 
from this analysis that there was a 2.3:1 false signal to background ratio for 
basic fuchsin bleedthrough.  Therefore, in order to deem a region as 
positively stained for FRFP, a signal to background ratio threshold of 7:1 
was applied. When the FRFP only specimen was viewed under the basic 










crossover of FRFP into basic fuchsin images. As a result, a 3:1 signal to 
background ratio was used to determine a positive staining for basic fuchsin. 
Any objects of interest that were less than these established signal to 
background ratios were deemed unstained for their respective dyes. 
4.2.9 FRFP Co-Localization Assessment 
To determine the degree of FRFP binding to microdamaged regions, 
the co-localization of FRFP and basic fuchsin to both micro cracks and the 
surrounding osteocytes were assessed using the following equations: 










A 50 micron region of interest was established around each crack to 










50 µm away from any microdamage sites were chosen and analyzed to 
determine the degree of osteocyte co-localization in non-damaged regions.  
4.2.10 Annexin-Vivo Confocal Microscopy Parameters 
After euthanasia both loaded and unloaded forelimbs were excised 
and fixed in 10% neutral buffered formaldehyde. Bones were then stained 
with 1% basic fuchsin using an established protocol [45] and rinsed in 100% 
ethanol. Samples were subsequently embedded undecalcified in poly methyl 
methacrylate (PMMA) for histology. Using a Buehler Isomet diamond-blade 
saw, 400 µm sections were then cut transverse to the longitudinal axis of the 
ulna. These sections were mounted on a plastic microscope slide and 
polished to a final thickness of 100 µm.  Sections were cover slipped and 
viewed using a 2-Photon Leica confocal inverted microscope system (SP5X 
Zeiss Confocal Microscope, Carl Zeiss MicroImaging, Inc., Thornwood, 
NY, U.S.A.), to identify bone areas stained with AV750 and basic fuchsin. 










accurate imaging protocol, the excitation and emission curves for both dyes 
were determined. Lambda scans were performed on cortical control 
specimens using the white light laser of the 2-Photon microscope. The first 
scan was performed on a specimen stained with basic fuchsin only, whilst 
the second scan was done on an AV750 stained sample. Excitation scans 
were performed in increments of 5nm between 480 nm and 670 nm whilst 
emission scans were performed in increments of 5nm between the range of 
500 nm and 800 nm. In order to image the basic fuchsin, an excitation of 
543nm was used, with an emission range of 553-613nm. The AV750 was 
imaged using an excitation laser of 670nm with an emission range of 700-
790 nm. These parameters were held constant for all images and ensured 
limited signal bleed through to the opposing channels.  
4.2.11 Apoptosis Image Analysis  
All images were scored using the pixel intensity tool provided by the 










validate the detected AV750 signal, a basic fuchsin control specimen was 
imaged under AV750 excitation and emission to determine the degree of 
crosstalk of basic fuchsin dye into the AV750 channel. It was determined 
from this analysis that there was a 2.8:1 false signal to background ratio for 
basic fuchsin bleedthrough.  Therefore, in order to deem a region as 
positively stained for AV750, a signal to background ratio threshold of 8:1 
was applied. When the AV750 only specimen was viewed under the basic 
fuchsin imaging conditions, it was observed that there was negligible 
crossover of AV750 signal into basic fuchsin images. As a result, a 3:1 
signal to background ratio was used to determine a positive staining for 
basic fuchsin. Any objects of interest that were less than these established 











4.2.12 Gray Value Threshold Affirmation and Distinguishing of Osteocyte 
Lacunae  
In order to quantify osteocytes in co-localized AV750 and basic 
fuchsin images, images were analyzed using the Leica LAS AF Image 
Browser (Version 2.6.0 Build 7266, Leica Microsystems CMS, Inc.) Using 
only the basic fuchsin channel, this software allows the user to trace out 
numerous regions of interests (ROI) in the image. Each individual osteocyte 
lacunae of interest, as identified by basic fuchsin staining around the lacunar 
wall of small elliptically shaped cells, was traced out in the basic fuchsin 
channel. A report sheet is then generated by the software that allows the user 
to see the maximum gray value within each ROI. This analysis is also 
automatically generated for the AV750 channel. Lacunae that were above 
the 3:1 threshold were counted as positive ROI’s and if the corresponding 










stained for AV750. Similar techniques were used when analyzing both 
damage and non-damaged regions.    
4.2.13 Apoptosis Quantification 
To determine the degree of AV750 binding to osteocyte lacunae 
surrounding microdamage, the co-localization of AV750 and basic fuchsin 
to surrounding osteocyte lacunae were assessed using the following 
equation: 





A 50 µm region of interest was established around each crack to 
assess osteocyte lacunae in the vicinity of microdamage. Regions of interest 
at least 50 µm away from any microdamage sites were chosen and analyzed 
to determine the degree of osteocyte lacunae co-localization in non-damaged 










a non-damaged region could be adequately imaged within the same field of 
view of the 40X objective, thus minimizing potential artifact from image 
acquisition parameters between fields. 
 
4.2.14 Statistical Analysis 
Differences between Brtl/+ and WT in the percentage of osteocytes 
co-localized with FRFP and basic fuchsin, and the average percentage of 
crack lengths co-localized with FRFP and basic fuchsin were assessed by t-
test.  Fisher’s exact test was used to compare genotype differences in the 
proportion of cracks positively labeled with FRFP. Differences between 
treated and untreated in average percentages of osteocytes co-localized with 
AV750 and basic fuchsin were also assessed using t-test. Analyses were 
performed using GraphPad Prism 4.0. Differences were considered 











4.3.1 Brtl/+ microcracks demonstrate higher affinity for FRFP 
FRFP binds avidly to portions of microcracks and surrounding 
osteocyte lacunae, with overlapping fluorescence with basic fuchsin at 
multiple sites (Figure 4-2).  Brtl/+ specimens demonstrate  a higher 
percentage of crack length co-localized with FRFP and basic fuchsin (66%), 
as compared to WT (24%) (p<0.05) (Figure 4-4, Table 4-1). One particular 
Brtl/+ micro crack had a longer FRFP label than its basic fuchsin labeling, 
leading to a 127% co-localization percentage.  Sixteen out of 18 (89%) 
cracks for Brtl/+ were positively labeled with FRFP (Table 1). In contrast, 
12 out of 23 (52%) WT cracks showed positive labeling with FRFP (Table 
1). There were, however, two cases in WT where cracks were labeled only 
with FRFP and were not stained with basic fuchsin.  Therefore, these two 










localized crack lengths in WT, as their inclusion would obscure the 
numerical analysis.  
4.3.2 WT osteocyte lacunae demonstrate high affinity for FRFP near 
damaged regions 
WT specimens demonstrate a higher percentage of osteocytes co-
localized with basic fuchsin and FRFP (41%) than their Brtl/+ counterparts 
(20%) (p<0.05) (Figure 4-5, Table 4-1). Furthermore, 4 out of 17 cracks 
analyzed for Brtl/+ (23.5%) had none of their surrounding lacunae stained 
with FRFP. In contrast, only 1 out of the 23 cracks (4%) for WT showed no 
binding of FRFP to any of their surrounding osteocytes (Table 4-1). 
4.3.3 WT and Brtl/+ display similar levels of FRFP o-localization in non-
damaged regions 
A region of interest at least at least 50 microns away from any 










these osteocytes showed that both WT (n=17 images) and Brtl/+ (n=12 
images) specimens displayed similar levels of FRFP binding (29.26% and 
29.93% respectively) (Table 4-1).  
4.3.4 WT and Brtl/+ display similar vascular and osteocyte lacunae 
densities  
In order to determine if there were any additional factors that could 
potentially impact drug delivery to microdamage sites, the vascular and 
osteocyte lacunae densities were calculated for each crack. These densities 
were assessed within the field of view that the image of the crack was taken. 
Osteocyte lacunae were defined in basic fuchsin images as small elliptically 
shaped regions which had void spaces in the middle and had basic fuchsin 
staining on the perimeter (lacunae wall). Osteocyte lacunae are typically 
40µm2 in cross sectional area. Vascular spaces possessed a more fully 
rounded structure and had very little if any void spaces. These spaces were 










sectional area (Figure 4-6). All osteocyte lacunae and vascular supplies 
were counted and areas were calculated using ImageJ. Results show that 
there were no significant differences in either osteocyte densities in Brtl/+ 
versus WT (998.9 ± 290.3 osteocytes/mm2 and 1119.9 ± 160.2 
osteocytes/mm2 respectively; p = 0.1) or vascular densities in Brtl/+ versus 
WT (28.1 ± 18.5 vessels/mm2 and 21.7 ± 9.7 vessels/mm2 respectively; p = 
0.16).  
4.3.5 Osteocyte apoptosis spatial distribution around peri-damaged 
regions 
AV750 localized to the regions within the osteocyte lacunae, which 
suggests that they localized to osteocytes (Figure 4-7). When pooled 
together, treated specimens demonstrate a lower percentage of osteocyte 
lacunae undergoing apoptosis (22.1%) than their untreated counterparts 
(35.7%) (p<0.05) in regions within 50 µm of a crack (Figure 4-8 and Table 










in Brtl/+ untreated specimens surrounding microdamage (45.3%) when 
compared to WT untreated specimens (25.8%)(p<0.05) (Figure 4-8 and 
Table 4-2). Additionally, there is an increased level of osteocyte apoptosis 
surrounding Brtl/+ untreated specimens (45.3%) when compared to Brtl/+ 
treated specimens (26.9%) (p<0.05).    
4.3.6 Apoptosis spatial distribution around non-damaged regions 
Brtl/+ untreated specimens had higher levels of osteocyte apoptosis 
away from damage (28.17%) than non-damage areas in Brtl/+ treated 
specimens (19.48%) (p<0.05).  However, there was no significant difference 
seen in osteocyte apoptosis levels when comparing WT non-damaged treated 
regions (10.75%) and WT non-damaged untreated specimens (9.13%).  
When comparing across genotypes, there was a significant increase 
seen in the amount of apoptotic osteocytes away from damage in Brtl/+ 










increase in apoptotic osteocytes was seen in treated Brtl/+ non-damaged 
regions when compared to treated WT non-damaged regions (P<0.05). 
 When pooled together, there was a significant increase in the amount 
of osteocyte apoptosis seen near damage in untreated specimens (34.5%) 
when compared to treated specimens (22.1%) (p<0.05). However, there was 
only a trend towards a decrease in apoptosis in regions away from damage in 
treated specimens (14.8%) when compared to untreated specimens away 
from damage (19.0%) (p=0.153) (Figure 4-8 and Table 4-2) 
4.4 Discussion 
In this study we demonstrated, using a fluorescent-labeled 
bisphosphonate, that microcrack surfaces and surrounding osteocytes are 
prone to local bisphosphonate binding. Additionally, using the in-vivo 
fluorescent marker Annexin-Vivo 750, we showed that following 5 weeks of 
treatment with the bisphosphonate Alendronate, apoptosis levels 










to untreated specimens. Annexin-Vivo 750 has been used in other 
applications before [142-144], but to our knowledge, this is the first 
application to bone tissue. Bisphosphonates are commonly used for the 
treatment of low bone mass.  However their use has also been suggested to 
affect the amount of skeletal microdamage, both by altering the tissue 
material properties (e.g. through alterations of collagen cross-linking, 
increased tissue mineralization, and reduced microstructural interfaces), 
thereby leading to greater microdamage accumulation, as well as by direct 
interference with osteoclast repair of damaged tissue. This suggests that 
bisphosphonates could potentially regulate microdamage repair at multiple 
levels. The current study demonstrates that bisphosphonate may interfere 
with targeted microdamage repair directly by binding to microcrack surfaces 
and interfering with osteoclast repair at the site that needs it the most.  
Additionally, our results suggest that bisphosphonates may interfere with 










microdamage, thus suppressing the apoptotic signal required to induce 
targeted remodeling. With decreased fracture incidence being a crucial 
element in the quality of life of bisphosphonate treated patients, the 
implications of arrested microdamage repair are significant. 
In order to prevent detrimental accumulation of microdamage in 
healthy bone, damage can either be remodeled stochastically or through 
targeted repair. The effect of bisphosphonates on damage repair is multi-
faceted as it affects the induction of osteocyte apoptosis [129-131], the 
apoptotic activation of the osteoclast-stimulating pathways [133, 134], and 
the eventual targeting and repair of damage by osteoclasts themselves [40]. 
The efficacy of bisphosphonates in treating bone fragility [18-23] cannot be 
ignored, however, there is a concern regarding the long-term effects of 
bisphosphonates on the inhibition of targeted repair of skeletal 
microdamage.  Extended bisphosphonate treatment has been correlated with 










which may in turn have detrimental effects on the bone’s mechanical 
integrity [24-26, 28]. To date, there has been no direct relationship to link 
extended bisphosphonate therapy with atypical, low-energy subtrochanteric 
femoral fractures observed in osteoporotic patients undergoing treatment 
[29, 30]. The results of the present study suggest that the binding of 
bisphosphonates to microdamage and the surrounding osteocytes may lead 
to arrested microdamage repair and could represent a contributing factor 
toward these subtrochanteric femoral fractures. Furthermore, these 
observations could also have strong implications for fracture prone 
osteogenesis imperfecta (OI) patients on bisphosphonates who may be more 
susceptible to microdamage accumulation as suggested by animal models 
[17, 31]. With both OI and osteoporosis patients being increasingly 
susceptible to critical bone failure, any treatment modalities that potentially 










In this study, we used the Brtl/+ mouse which is a heterozygous 
model for type IV OI [38]. The genotype arises from a Gly349Cys 
substitution in COL1A1, and demonstrates a low ductility phenotype [15]. 
Wild type (WT) specimens were used as a model to determine the effects of 
bisphosphonate binding in bone with unaffected collagen. Brtl/+ ulnae, 
subjected to similar strain matched loads as their WT counterparts, 
demonstrated higher levels of FRFP co-localization to micro cracks. The 
opposite was true for osteocytes in the immediate surrounding regions of 
micro cracks, as Brtl/+ specimens had a lower percent FRFP osteocyte co-
localization than their WT counterparts. This data suggests that there may be 
mechanisms that allow Brtl/+ cracks to serve as depositories for FRFP.  
Damage to bone tissue has been shown to alter interstitial fluid flow in 
the surrounding areas and vascular tracer studies have shown that these 
agents tend to pool in these areas [138, 139]. Tami et al. provided several 










surrounding lacunae [138]. The first of these mechanisms is a crack acting as 
a reservoir for mass and fluid flow. In this proposed mechanism, a crack 
serves as an additional fluid space in the lacunocanalicular network, leading 
to a much slower increase in concentration up-stream from the crack. The 
second such mechanism is that of a crack serving as a wall. Here, the crack 
essentially occludes fluid flow to osteocytes down-stream of the crack, 
whilst regions up-stream experience an increase in concentration. In the third 
scenario, where a crack can function as a sink, the crack prevents fluid flow 
to the down-stream osteocytes similar to a wall, with the notable exception 
that volume flow and the concentration of molecules are decreased up-
stream from the crack [138].   
In the present study, both WT and Brtl/+ osteocytes exhibit similar 
degrees of FRFP binding in regions away from damage. However, the 
introduction of microdamage has contrasting effects on the surrounding 










Brtl/+ cracks analyzed functioned as walls for their respective osteocytes, as 
there was no binding of FRFP to any of the surrounding osteocytes. 
Conversely, 4% of WT cracks served as walls. Thus the remaining cracks in 
both WT and Brtl/+ could either function as reservoirs or sinks. We can infer 
from our data that the majority of these remaining cracks likely served as 
sinks, as both WT and Brtl/+ showed large percentages of osteocytes  that 
did not express co-localization of FRFP. In these situations, most, but not all 
of the FRFP was prevented from being delivered to the regions surrounding 
damage.  
When comparing the non-damaged regions of WT specimens to the 
damaged regions, it appears that there is a spatial preference towards an 
accumulation of FRFP around regions of cracks. This is seen from the 10% 
increase in osteocyte co-localization in damaged regions compared to non-
damaged regions. The reverse is true for Brtl/+, as there is a 10% decrease in 










WT cracks are less permeable than their Brtl/+ counterparts, and may be 
acting as a wall, thus leading to an increase in FRFP in the surrounding 
osteocytes. Brtl/+ cracks on the other hand appear to act as depositories and 
seem to be more permeable, thus showing lower co-localization of FRFP 
labeling of osteocytes surrounding Brtl/+ microcracks  than WT. 
These observations pose interesting questions regarding targeted 
microdamage repair and the role that bisphosphonates play in this repair 
process. While the intention for treatment with bisphosphonates is to 
increase skeletal mass, they may concomitantly prevent targeted repair from 
occurring on two separate fronts.  The first of which is the prevention of 
osteocyte apoptosis [40, 129, 145], which has been proposed as one of the 
important first steps in the targeted bone remodeling process. It has been 
shown that a damaged osteocyte-canalicular system (through microcracks 
for instance) will result in osteocyte apoptosis, followed by the recruitment 










resorption and repair of damaged regions in bone [40]. Prevention of this 
activating first step by inhibiting osteocyte apoptosis could lead to a 
decreased rate of repair. The second front on which bisphosphonates 
potentially affect microdamage repair is through inhibition of osteoclast 
remodeling.  Bisphosphonates bind to bone, and upon uptake by osteoclasts 
during the resorption process, result in cell toxicity, thus reducing bone 
turnover and increasing bone mass. While bisphosphonates globally 
downregulate stochastic bone remodeling across the skeleton, the present 
results support the notion that bisphosphonates bind directly to microcrack 
surfaces and may directly inhibit bone turnover at the site of microdamage 
itself. This could inherently lead to an unrepaired crack that is allowed to 
propagate without repair, resulting in critical crack length growth and 
subsequent failure. 
When data for WT treated and Brtl/+ treated specimens were pooled 










specimens, a significant difference was observed in the levels of apoptotic 
osteocytes surrounding microdamage. Treated microcracks possessed lower 
levels of apoptotic osteocytes than their untreated counterparts. This data is 
supported by other studies that have shown Alendronate suppressing 
osteocyte apoptosis following cyclic fatigue loading [129, 146]. 
Furthermore, the observation of increased levels of osteocyte apoptosis 
observed in Brtl/+ untreated specimens both near and away from damage 
when compared to WT untreated specimens raises a few questions. Studies 
have demonstrated a disproportionate up-regulation of osteoclast and 
osteoblast activity in OI patients, with an overall imbalance favoring 
osteoclast resorption [13, 14]. It is not fully understood the physiological 
reasons for this, but our observations of increased osteocyte apoptosis 
surrounding Brtl/+ cracks raises the possibility that osteocyte apoptosis may 










As microdamage levels increase in a healthy individual, the inherent 
remodeling processes of bone are activated for microdamage repair [66]. 
The increased up-regulation of osteocyte apoptosis surrounding microcracks 
in Brtl/+ could be a function of a genetically caused whole body increase, or 
could be the Brtl/+ mouse’s way of trying to repair microdamage through 
specific targeting of damage. When data for treated specimens was pooled 
together, it was observed that the amount of osteocyte apoptosis away from 
damage was only marginally lower than the amount of osteocyte apoptosis 
in non-damaged regions for untreated specimens (19.0% vs. 14.8%). The 
amount of osteocyte apoptosis seen away from damage is similar to the 
levels seen in work done by Verborgt et al. who showed about 15% of 
osteocytes imaged being TUNEL positive for apoptosis [129].  It is likely, 
that even though bisphosphonates may inhibit osteocyte apoptosis, the lack 
of microdamage in these areas would result in a lack of apoptosis of 










likely to only have marginal effects on preventing any normal apoptosis that 
would be occurring in the non-damaged bone tissue.  This data supports the 
notion that microdamage is necessary to induce osteocyte apoptosis. 
Studies have shown that as the Brtl/+ mouse ages, a cellular 
uncoupling leads to a decline in bone formation [16]. During this process 
there is an increase in osteoclast number and function, whilst osteoid 
production by osteoblasts is reduced. While the cellular asynchrony favoring 
osteoclast formation and activity in Brtl/+ is a result of an increase in 
osteoclast precursors in the Brtl/+ marrow [16], the RANKL/OPG ratio is 
unchanged and the factors regulating increased osteoclasts have yet to be 
described. However, there have been studies that have postulated and 
demonstrated that viable osteocytes do in fact play a role in suppressing 
osteoclastic attack [147-152]. It is possible that the decreased levels of 
osteocyte viability demonstrated through increased levels of osteocyte 










osteoclast activity and thus subsequent elevated levels of osteoblast activity. 
It is unknown whether the increased levels of microdamage seen in the 
Brtl/+ mouse explains the elevated levels of osteocye apoptosis observed, 
however it still remains unclear the specific physiological reasons for this. 
There is evidence in humans that apoptotic osteocytes are more common in 
young growing bone experiencing a high degree of resorption than in 
relatively quiescent normal adult human bone [153]. The same could be 
applicable to the Brtl/+ mouse at 8 weeks of age, but the question as to why 
apoptosis levels in Brtl/+ is higher than WT remains.  
Our data shows that Brtl/+ cracks have significantly more binding of 
FRFP (66%) than their WT counterparts (24%). It is possible that this may 
result in a protective mechanism for Brtl/+ bones by preventing the delivery 
of bisphosphonate to surrounding osteocytes. This could potentially allow 
osteocyte apoptosis, and thus osteoclast activation, to occur normally, but at 










suffice for short and low dose bisphosphonate treatments as our apoptosis 
evidence suggests that with extended treatment, bisphosphonates are 
eventually metabolized by Brtl/+ osteocytes resulting in the prevention of 
their apoptosis in areas surrounding microdamage. The presence of bone 
microdamage has been shown to result in a decrease in lacunocanalicular 
interstitial fluid flow, which over time has been implicated in the increase of 
remodeling activity [154]. It is unclear whether the increased remodeling 
activity seen in Brtl/+ [16] is caused by an increase in inherent microdamage 
[17], but the presence of bisphosphonates could potentially obstruct the 
natural processes that Brtl/+ deploys to repair its damage.  
We observed that treated Brtl/+ cracks had lower levels of osteocyte 
apoptosis than their untreated counterparts. We suspect that delivery of 
bisphosphonate to these osteocytes may have increased over time as Brtl/+ 
cracks quickly became saturated with bisphosphonate. This then likely 










Furthermore, we observed an insignificant decrease in osteocyte apoptosis 
levels between WT treated and WT untreated cracks. It is possible that the 
WT cracks may have absorbed bisphosphonates during the treatment 
protocol, thus preventing excessive absorption in the surrounding osteocytes. 
It is unclear however how much bisphosphonate is actually necessary to 
initiate an anti-apoptotic response and at what time point this is actually 
initiated in the treatment protocol. It is apparent however that in the case of 
Brtl/+, bisphosphonates appear to be potentially suppressing apoptosis of the 
osteocytes and could be preventing the first step in potential microdamage 
repair [129]. In fact, in both WT and Brtl/+, treatment with bisphosphonate 
appears to bring apoptosis levels near damage and away from damage to 
similar levels, as no significant differences were observed when comparing 
these two regions in both genotypes. Even though it is unclear whether 










patients could be significant, as bisphosphonates could be suppressing the 
body’s attempt of damage repair [129, 147].      
Studies have shown that bisphosphonate binding and depth of penetration 
once leaving the vasculature is strongly impacted by the degree of 
mineralization [155, 156], with lower affinity bisphosphonates penetrating 
deeper into the cortical bone canalicular network, including the 
lacunae[157]. Small differences in Brtl/+ and WT mineralization [88] may 
be responsible for the observed differences in bisphosphonate binding 
between genotypes. Alternatively, differences in microstructural features 
such as lacuno-canalicular connectivity or microdamage complexity may 
alter local availability of surface binding sites. We found no significant 
differences between osteocyte density and vascular channel density between 
Brtl/+ and WT in these studies, suggesting minimal effect of these 










The observations of this study pose interesting questions regarding 
targeted microdamage repair and the role that bisphosphonates play in this 
process. While the intention of treatment with bisphosphonates is to increase 
skeletal mass, the current findings suggest that bisphosphonates may have 
the potential to prevent targeted repair from occurring on two separate 
fronts. Osteocyte apoptosis, induced following damage to the osteocyte-
canalicular system, has been shown to be required for the activation of 
osteoclasts during targeted microdamage repair [129-131, 158]. However, 
bisphosphonates have been shown to inhibit osteocyte apoptosis in the 
presence [27, 135] and absence [132] of microdamage. Our current findings 
suggest that bisphosphonate delivery to osteocytes near microdamage is 
consistent with the finding of reduced osteocyte apoptosis, and reduced 
microdamage repair as shown by others[135]. Secondly, while 
bisphosphonates globally downregulate stochastic bone remodeling across 










directly inhibited at the site of microdamage itself, leading to persistence, 
and possible propagation of the crack over time.   
There were limitations to this study. When looking at a FRFP only 
specimen, one can discern finer details and more osteocytes than in a dual-
stained specimen. Due to the slight overlap in emission spectra of both basic 
fuchsin and FRFP, a smaller band width had to be used for FRFP to 
delineate both dyes and prevent nonspecific basic fuchsin bleed through.  
This resulted in a higher threshold and thus a lower signal observed for 
FRFP and therefore an underestimation of the fluorescent bisphosphonate 
binding. It is important to note then, that the co-localization results shown in 
this study are a conservative representation of the data. Additionally, the fact 
that analysis of cracks was not confined to any one region of the ulna, but 
was rather analyzed throughout the cortex based on where damage itself was 










In summary, these findings suggest a dual mechanism for 
bisphosphonates to inhibit targeted microdamage repair, by binding to 
surrounding osteocyte lacunae, and potentially inhibiting osteocyte apoptosis 
required for osteoclast signaling, and by binding directly to the microcrack 
itself, potentially inhibiting bone resorption directly at the site that requires it 
the most.  It remains to be seen whether these findings are associated with 
emerging evidence of low-trauma, atypical fractures in osteoporotic patients 
on extended bisphosphonate therapy, or whether the accumulation of 
microdamage in patients with OI may further facilitate bone fragility in the 
long run of that disease.  The ability of bisphosphonates to bind directly to 
bone, and not circulate as other anti-resorptives such as calcitonin or 
denosumab, suggest that they may impart a unique interaction with 













Figure 4-1: Annexin-Vivo 750 apoptosis verification  
The signaling of hypertrophic chondrocytes demonstrates that Annexin-Vivo 750 
(G-I) is in fact detecting an apoptotic signal. Hypertrophic chondrocytes are known to be 
apoptotic. This is verified against TUNEL/Hoechst staining which is the gold standard 
for apoptosis staining (A-C). Corresponding negative controls are attached to 











Figure 4-2: Local co-localization of FRFP and basic fuchsin 
Image (A,D) showing basic fuchsin labeled crack and surrounding 
osteocyte lacunae, (B,E) the corresponding FRFP labeled image, and (C,F) 
a superimposed image of FRFP and basic fuchsin is also illustrated with 
labeled examples of co-localized osteocyte lacunae and co-localized 
microdamage. Note the binding of FRFP to the lacunar wall as opposed to 












Figure 4-3: Excitation and emission spectra for basic fuchsin and FRFP 
Excitation and emission spectra used during imaging of specimens stained with both 











Figure 4-4: % co-localized crack lengths in WT and Brtl/+  












Figure 4-5: % co-localized osteocytes in both WT and Brtl/+ 
Percentage of co-localized osteocytes in both WT and Brtl/+ specimens near 














Figure 4-6: Blood vessel vs. osteocyte lacunae 
Image showing the size and morphological differentiation between a blood vessel 
structure and an osteocyte lacunae. Vessel structures are approximately 250µm2 in area 











Figure 4-7: Microdamage and osteocyte apoptosis co-localization 
Representative image of microdamage stained with basic fuchsin (A) and its 
corresponding bright field image (B). Panels D-L represent basic fuchsin stained cracks 
and osteocyte lacunae and Annexin-Vivo stained osteocytes which indicate apoptosis. 
Note the cellular nature of Annexin-Vivo, as seen by central localization within osteocyte 
lacunae. Panels J-L shows demonstrates that osteocytes closer to cracks are more stained 












Figure 4-8: Spatial distribution of osteocyte apoptosis 
Figure displays the percentage of osteocytes undergoing apoptosis in regions near 
and away from damage in both treated and untreated genotypes. Pooled values are 
represented as the last 2 groups. *: p<0.05 near damage vs. away from damage within 
treatment group. α: p<0.05 Brtl/+ treated away from damage vs. WT treated away from 
damage. # : p<0.05 Brtl/+ untreated near damage vs. WT untreated near damage. ⱡ : 
p<0.05 Brtl/+ untreated away from damage vs. WT untreated away from damage. $: 













Table 4-1: Data showing co-localization of FRFP stained cracks and        
osteocytes as well as combined effects 
 
* 2 cracks were not included for crack length co-localization calculations in WT. 
These cracks had no basic fuchsin binding but did show FRFP labeling. 
# 1 Crack was not included for Brtl/+ osteocyte co-localization calculations. This 
crack had no basic fuchsin or FRFP stained osteocytes in the surrounding vicinity. 













Table 4-2: Osteocyte apoptosis data 
 
*: p<0.05 near damage vs. away from damage within treatment group. α: p<0.05 Brtl/+ 
treated away from damage vs. WT treated away from damage. # : p<0.05 Brtl/+ untreated 
near damage vs. WT untreated near damage. ⱡ : p<0.05 Brtl/+ untreated away from 
damage vs. WT untreated away from damage. $: p<0.05 Treated combined near damage 












Low bone mass diseases such as osteoporosis and osteogenesis 
imperfecta (OI) are a significant concern in our society today. Osteoporosis 
affects over 50 million Americans 50 years and older [9] , while OI, despite 
being rarer, affects around 50,000 people in the United States. Together, 
these diseases account for the more than 2 million fragility fractures in the 
United States each year, and account for over $20 billion dollars in health 
care expenses [10]. A disease such as OI, despite being less common in 
society, is still very important to investigate clinically as well as in basic 
science, as the physical and emotional toll of the disease affects not only the 










children who are wheelchair bound and merely want to enjoy their childhood 
like anyone would without the worry of suffering the frequent fractures that 
are known to come with the disease. 
Finding an effective solution to alleviate the conditions of OI is a 
multi-pronged system and many scientists have been investigating these 
potential solutions. Some are looking at cellular and gene-therapy [159, 
160], which is focused on actually targeting the root causes of the disease, 
while others are looking at drug therapies such as parathyroid hormone 
(PTH) [161], RANKL inhibitors [162], and sclerostin antibody [163]. 
However, the most common form of treatment that exists are 
bisphosphonates which aim to increase bone mass and strength through 
osteoclast-mediated bone resorption.  Despite the clinical success seen in 
improved vertebral strength, increased BMD, and reduced vertebral fracture 
rates, there is still no clear improvement seen on fracture rates in the long 










It is common practice to use animal models as surrogates to 
investigate the mechanical properties of low bone mass diseases as well as 
the effects of their treatment modalities. Animal models that have been used 
to investigate bisphosphonate treatment have shown compromised 
mechanical integrity with long term treatment. In addition, bisphosphonates 
have been implicated in preventing microdamage repair through the 
inhibition of osteoclast targeting mechanisms. In fact, the increased 
occurrence of sub-trochanteric fractures seen in the past decade after long 
term bisphosphonate use has been linked to the inhibition of damage repair 
in this high stress site.  
For the duration of this thesis, we used a mouse model for OI, the 
Brtl/+ mouse which replicates Type IV OI. The use of a mouse model for 
this study comes with its advantages and disadvantages. The primary 
advantage of using any animal model is that they serve as good surrogates 










provided a good starting point model for human bone, without the obvious 
complications of dealing with human subjects. The mouse allows us to study 
the developmental changes of bone as it ages much more quickly than other 
larger animals. The average mouse lives approximately 2 years while the 
average human lives about 75 years. This translates to quicker turn around in 
research time. For example, the current study was interested in looking at the 
potential effects in pediatric patients with OI. The mouse enters full puberty 
at 8 weeks of age, which is ideal with regards to treatment with 
bisphosphonate. In 5 weeks of treatment, we are effectively able to treat the 
mouse from a very young age (3 weeks) until puberty (8 weeks), which 
approximates the treatment of most pediatric OI patients. In larger animals 
this would require higher dosages (due to body size) as well as longer 
treatment durations due to longer maturity times. In addition, mice are 
significantly cheaper to house and maintain than larger animals, for 










thus allowing for larger numbers to be studied. The mouse also allows us the 
ability to more cost effectively perform genetic engineering through knock-
in and knock-out models, thus allowing us to replicate diseases such as Type 
IV osteogenesis imperfecta more effectively than in larger animals. 
Additionally, classical genetics in a mouse has been well established and 
there is large availability of different genetic strains. The small size of the 
mouse generally corresponds with less reagents, smaller processing times 
and is generally better for spatial resolution in fluorescence imaging due to 
the smaller size of the tissue. 
Despite the advantages listed above, there are disadvantages of using 
the mouse including the obvious observation that mice are not humans. The 
physiology of the mouse is different from a human. For example, the aspect 
ratio of vertebrae as well as the functional purpose of the forearm is different 
in mice when compared to humans. On a macroscopic bone tissue level, the 










on the propagation of cracks. It is proposed that in humans, osteons and the 
lamellar structure of bone can arrest crack growth, thus preventing cracks 
approaching critical lengths. Additionally, the apparent absence of 
intracortical remodeling and bone modeling units in the mouse may result in 
the development of more detrimental cracks, which may otherwise be 
repaired in human bone. This may raise the question of whether or not 
microdamage accumulation in the mouse (in the potential absence of repair) 
is an adequate representation of the potential effects that may or may not 
arise in humans. Overall, the Brtl/+ mouse is an effective model for use in 
this study as it demonstrates similar mechanics, post-pubertal adaptations, 
up-regulation in bone remodeling, and has a genetic mutation that replicates 
the disease of a Type IV OI patient. 
The intention of this thesis was to form a clearer picture of the 
interplay between microdamage and bisphosphonate therapy, as well as any 










microdamage. As mentioned earlier, OI patients suffer from increased bone 
fractures. It is not unreasonable to assume that with an increase in fracture 
propensity, comes an increase in inherent damage in OI bone.  Aim 1 of this 
study looked at whether or not OI bone is more susceptible to microdamage 
accumulation than a healthy bone. We hypothesized that the Brtl/+ mouse is 
more susceptible to microdamage accumulation compared to wild type (WT) 
controls. In this study we found that Brtl/+ is in fact more prone to 
microdamage accumulation, not only following cyclic loading, but during 
normal ambulation as well. In addition, we saw good correlations between 
fracture toughness and propensity to accumulate microdamage in Brtl/+.  
The outcome of this study highlights the potential that OI patients may 
possess increased levels of microdamage in their bones, which likely leads 
to whole bone loss of structural integrity.  
Having determined that Brtl/+ does in fact possess more microdamage 










of bisphosphonate therapy in the Brtl/+ mouse. In particular we were 
interested in assessing whether or not an extended treatment protocol would 
adversely impact the microdamage content as well as fracture toughness 
properties in the growing phase of the Brtl/+ mouse. As bisphosphonates are 
regularly administered to children who are rapidly growing, it was important 
to determine whether treatment could potentially adversely affect the bone 
negatively. We set out to test the hypothesis that bisphosphonate treatment 
would lead to an increase in microdamage content and a concomitant 
decrease in bone material properties in the Brtl/+ mouse.  
Aim 2 provided its fair share of unexpected challenges, but at the 
same time still yielded important results that shed light on some potential 
effects of bisphosphonate treatment. It is apparent that bisphosphonate 
treatment in the Brtl/+ mouse may adversely affect the bone’s cycle fatigue 
durability. Although cycle fatigue was not tested directly, the observation of 










surface strains than untreated specimens, suggest that bisphosphonates could 
possibly be affecting the collagen structure on the microscopic level. We 
proposed that the increased levels of collagen crosslinking is likely playing a 
key role in this as well as the moderate trends towards a decrease in fracture 
toughness observed in treated specimens. It is also possible that the retention 
of calcified cartilage at the proximal metaphyseal site of the forearm could 
potentially explain the occurrences of premature fracture at the elbow 
region. This area could serve as a structural weak point for the entire 
forearm and may be more prone to fractures. 
For future work, the proposed decrease in fatigue durability with 
bisphosphonate treatment will be investigated, possibly through cyclic 
fatigue of femurs using 3-point bending. We hypothesize that after 5 weeks 
treatment, the fatigue life under high strain cyclic loading(~3500 
microstrain) will be lower than untreated bones in both Brtl/+ and WT 










to 12 weeks would provide some valuable extensive data to the current 
study. Studies done by Uveges et al. demonstrated more pronounced 
differences with bisphosphonate treatment after 12 weeks of treatment as 
opposed to 6 weeks of treatment. We hypothesize that the current trend of 
decreased fracture toughness will become more significant with extended 
treatment into adulthood of the mouse.  Additionally, we suspect that the 
level of baseline microdamage in unloaded limbs after 5 weeks of treatment 
may probably be too short to see any significant differences in microdamage 
levels when compared to untreated limbs. As such, we hypothesize that there 
will be more baseline levels of microdamage in the unloaded treated limbs 
than in the unloaded untreated limbs, following 12 weeks of treatment.  
Our current observations of no differences in microdamage in 
unloaded limbs does suggest that bisphosphonates may work perfectly fine 
in low strain situations, but the implication of structural integrity does 










nature of the bisphosphonate treatment study in Aim 2, our data shows that 
bisphosphonates are having an effect on some inherent material properties 
and are the likely culprit in comparable microdamage levels observed in 
Brtl/+ and WT mice despite the application of lower strains in treated 
specimens. Most clinical uses of bisphosphonates are long term, and with 
observations that long term use tends to lead to a decrease in bone’s 
mechanical integrity, there is the potential that the long term remodeling of 
microdamage may also be compromised. This would be somewhat 
counterintuitive to the notion of bisphosphonates improving whole bone 
strength. For Aim 3 we wanted to investigate the targeting and spatial 
distribution of bisphosphonates as well as any potential impacts on osteocyte 
apoptosis, which has been proposed as a key step in the damage repair 
process.   
This particular study took advantage of fluorescent probes and the 










of an in-vivo fluorescent bisphosphonate and fluorescent apoptosis marker, 
we were able to co-localize damage with its surrounding osteocyte lacunae. 
We firstly observed that following cyclic loading, the bisphosphonate 
fluorophore bound itself not only to osteocyte lacunae, but to the actual 
microcracks. This observation in both Brtl/+ and WT has significant 
consequences for the concept of targeted damage repair as bisphosphonates 
have been implicated as inhibitors of osteocyte apoptosis which is a 
proposed first step in damage repair.  
Our osteocyte apoptosis data provided some interesting possibilities 
that may play some role in the observed increase in up-regulation of bone 
remodeling seen in Brtl/+ (and OI). We noted a stark increase in osteocyte 
apoptosis surrounding microdamage in untreated Brtl/+ specimens when 
compared to WT untreated specimens. This raises the question of the 
possibility that the up-regulation of remodeling may happen concomitantly 










osteocytes keep osteoclasts away, but could Brtl/+ be compensating for its 
increased levels of microdamage by up-regulating all cellular processes 
including osteocyte apoptosis? 
Some burning questions arise from the observations of this study. 
Firstly, are RANKL expressions decreased in bisphosphonate treated bone in 
the Brtl/+ mouse? The decrease in osteocyte apoptosis levels suggest that it 
would be, as it is understood that RANKL triggers osteoclast recruitment. 
Studies done by Kurata and colleagues indicate that damage to osteocytes 
does result in the production of RANKL and other soluble factors that are 
necessary for the initial phase of osteoclastic cell formation [164]. If this 
observation is indeed somewhat linearly correlated, it would be highly 
interesting to see if bisphosphonates could be used in a regulatory fashion to 
lower osteocyte apoptosis levels to “normal” levels. One could then 










steady state level, or if they remain equally up-regulated regardless of 
pharmacological intervention. 
We hypothesize that the observed increases in remodeling activity 
seen in the Brtl/+ mouse is partially due to the increased levels of osteocyte 
apoptosis that we have observed in this thesis. We propose that the increase 
in osteocyte apoptosis in Brtl/+ results in increased levels of RANKL, and 
subsequent osteoclast activity. Additionally, we suspect that bisphosphonate 
treatment will suppress RANKL levels in the Brtl/+ mouse, by suppressing 
osteocyte apoptosis. To test this hypothesis, baseline RANKL levels in 
Brtl/+ would be measured using immunohistochemical staining and light 
microscopy at 8 weeks and 16 weeks of age. These results will be compared 
to Brtl/+ animals that have been treated with bisphosphonate from 3 weeks 
of age until 8 and 16 weeks of age. The aim of this experiment would be to 
determine if bisphosphonates could potentially be used to regulate 










the correct dosage, clinicians could potentially use bisphosphonates as a 
regulatory mechanism for patients with high bone turnover diseases.   
Several other interesting questions remain to be tested that could shed 
further light on some of the questions addressed in this thesis. Firstly, 
attaining microscopy capabilities that can delineate both basic fuchsin, and 2 
far-red flourophores such as Annexin-Vivo 750 and FRFP into 3 distinct 
signals would be an advanced capability. This would enable us to co-localize 
microdamage, bisphosphonate delivery, as well as osteocyte apoptosis in one 
scan. This would enable us to determine if bisphosphonate presence strongly 
correlates with osteocyte apoptosis. We hypothesize that cells which 
demonstrate bisphosphonate binding (through FRFP localization) will be 
less likely to undergo apoptosis (indicated by AV750 localization). This 
study would aim to investigate the direct impact of bisphosphonate treatment 










Additionally, the question of microdamage repair in the mouse still 
remains somewhat of a white whale. Does it or does it not exist? Firstly it 
would be interesting to investigate if microdamage accumulates in the Brtl/+ 
mouse with age. Testing microdamage levels at 3,5,7,9,11 and 13 weeks of 
age would give us a good idea of whether damage levels increase or simply 
remain the same over time. Once this is determined, the next logical step 
would be to determine if remodeling of damage exists. This could be done 
by having a set of Brtl/+ and WT animals (n=15/group) loaded at 8 weeks of 
age and a control group of n=15/group left unloaded. Over the course of the 
next 8 weeks, 3 animals would be sacked every week and the levels of 
microdamage could be assessed to determine if loaded limbs eventually 
converged upon the unloaded animals. We hypothesize that microdamage 
levels will increase linearly over the course of several weeks. This 
experiment is a very “expensive” experiment however as it would likely 










Additionally, if remodeling in a mouse does exist, identifying the time point 
it begins will prove challenging.   
Another experiment worth pursuing is investigating whether or not 
similar levels of microdamage exist in other OI mouse models such as the 
Mov 13 mouse. The heterozygous Mov 13 mouse is different from the Brtl/+ 
mouse in that it carries a provirus that prevents the initiation of the 
transcription of the α1(I) collagen gene [165]. This mutation has been 
associated with structurally normal type-1 collagen, but at a 50% decrease in 
quantity [56]. Mechanical tests have verified that Mov 13 in fact replicates 
Type I OI [56]. Assessing the levels of baseline microdamage and 
subsequently determining the impact of bisphosphonate therapy in these 
mice would provide an interesting contrast to the current Brtl/+ mouse 
observations. The current suggestion that RANKL levels may be associated 
with increased microdamage and osteocyte apoptosis in Brtl/+ could be 










remodeling activity as the Brtl/+ mouse. We hypothesize that Brtl/+ bones 
possess more baseline microdamage and higher levels of osteocyte apoptosis 
than Mov 13. If this observation is correct, it could further support the notion 
that the high levels of microdamage in Brtl/+ could be partially responsible 
for the elevated remodeling activity observed in Brtl/+. Also, mechanical 
effects such as fracture toughness, as well as taking note if similar 
occurrences of premature fractures occur in the Mov 13 mouse following 
treatment will be assessed. The results of this study would provide 
information to aid clinicians in determining whether or not bisphosphonates 
are differentially better to administer to patients with simply low bone mass 
(Type I OI) or patients with increased bone turnover corresponding to 
decreased bone mass (osteoporosis or Type IV OI).   
This thesis showed that microdamage content and susceptibility to 
damage generation may play a role in bone fragility. Additionally, we 










through several targeting mechanisms and could potentially promote further 
fractures. Our work specifically focused on Type IV OI and made 
suggestions that the observations could be translated to other low bone mass 
diseases. From a clinical perspective, it is important to determine however if 
this observation of increased microdamage in other low bone mass diseases 
is an underlying trait of the condition. Hence looking at other models for low 
bone mass diseases for example Type I OI (Mov 13), Type III OI (oim 
mouse) and osteoporosis and determining if microdamage is an equal 
concern is an essential question to answer. We proposed that the binding of 
bisphosphonates to damage sites is a key way in which bisphosphonates lead 
to increased fragility. Hence assessing whether the binding characteristics of 
bisphosphonates are any different in these models will determine if the 
potential consequences are similar to our current study. 
 Our current studies serve as a caution to clinicians who use 










microdamage carefully. Using a RANKL inhibitor such as Denosumab 
which lowers osteoclast activity but doesn’t bind to bone tissue may be the 
best way to treat these patients. Additionally, patients who have been treated 
with bisphosphonates who are suspected to have higher levels of inherent 
damage may need to be placed on a drug holiday and switched off 
bisphosphonates onto an alternative such as Denosumab. Furthermore, these 
patients could also potentially benefit from using a treatment such as 
sclerostin-antibody which would also increase the level of bone mass 
without bone tissue binding issues. 
The results of this thesis and the additionally proposed studies can be 
used by clinicians in a somewhat precautionary fashion, if the correct 
information is at their disposal. If clinicians could be provided with iliac 
crest biopsies of their patients, they could potentially determine the levels of 
microdamage in their patients before prescribing a treatment option. 










bones may not be a prudent decision. With the evidence of bisphosphonate 
binding to microcracks and surrounding osteocyte lacunae, it is possible that 
bisphosphonates could prevent the repair of these cracks. This would be a 
greater concern if the patient had higher levels of baseline damage as you 
increase the likelihood of the prevention of a critical microcrack being 
repaired. Additionally, our observations of moderately reduced fracture 
toughness in concert with high strain loading demonstrating critical failures 
should prompt clinicians to make their patients aware that despite treatment 
with bisphosphonates and improved bone mass, there are still risks for 
fractures. Tempering and strictly monitoring patient’s physical activity is 
crucial to ensure that fractures in potentially weakened sites such as the 
metaphyseal regions of long bones is avoided.  
The above mentioned experiments are some of the unknown questions 
that would help somewhat close the loop in the OI-microdamage-










has helped to elucidate a few of these links. Further basic science studies are 
needed to help close the link. It is important to note however that the 
purpose of all of these studies is to help the patients who are afflicted with 
this disease. The findings of this thesis and the others that will subsequently 
follow will not only help the OI community, but will likely transcend to 













[1] Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak 
CYC. Severely Suppressed Bone Turnover: A Potential Complication of 
Alendronate Therapy. Journal of Clinical Endocrinology & Metabolism 
2005;90: 1294-1301. 
[2] Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and Diaphyseal 
Femur Fractures in Patients Treated With Alendronate: A Register-Based 
National Cohort Study. Journal of Bone and Mineral Research 2009;24: 
1095-1102. 
[3] Giusti A, Hamdy NAT, Dekkers OM, Ramautar SR, Dijkstra S, 
Papapoulos SE. Atypical fractures and bisphosphonate therapy: A cohort 
study of patients with femoral fracture with radiographic adjudication of 
fracture site and features. Bone 2011;48: 966-971. 
[4] Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, 
Steele B, Meulen MCH, Lorich DG, Lane JM. Association of low-energy 
femoral fractures with prolonged bisphosphonate use: a case control study. 
Osteoporosis International 2009;20: 1353-1362. 
[5] Park-Wyllie Ly. Bisphosphonate use and the risk of subtrochanteric or 










[6] Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate Use and 
Atypical Fractures of the Femoral Shaft. New England Journal of Medicine 
2011;364: 1728-1737. 
[7] Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for 
Osteoporosis — Where Do We Go from Here? New England Journal of 
Medicine 2012;366: 2048-2051. 
[8] Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, 
Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, 
Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, 
McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der 
Meulen MCH, Weinstein RS, Whyte M. Atypical subtrochanteric and 
diaphyseal femoral fractures: Report of a task force of the american society 
for bone and mineral Research. Journal of Bone and Mineral Research 
2010;25: 2267-2294. 
[9] Cooper C, Melton LJ. Epidemiology of osteoporosis. Trends in 
Endocrinology & Metabolism 1992;3: 224-229. 
[10] Holroyd C, Cooper C, Dennison E. Epidemiology of osteoporosis. 
Best Practice & Research Clinical Endocrinology & Metabolism 2008;22: 
671-685. 
[11] Rauch F, Glorieux F. Osteogenesis imperfecta. The Lancet 2004;363: 
1377-1385. 
[12] Byers PH, Cole WG. In Connective tissue and its heritable disorders 
molecular, genetic and medical aspects. . In: Royce PM, Steinmann B, 
editors. Osteogenesis Imperfecta. 2nd ed. New York: Wiley-Liss; 2002, p. 
385–430. 
[13] Brenner RE, Vetter U, Bollen A-M, Mörike M, Eyre DR. Bone 
resorption assessed by immunoassay of urinary cross-linked collagen 
peptides in patients with osteogenesis imperfecta. Journal of Bone and 










[14] Baron R, Gertner JM, Lang R, Vignery A. Increased bone turnover 
with decreased bone formation by osteoblasts in children with osteogenesis 
imperfecta tarda. Pediatric research 1983;17: 204. 
[15] Kozloff KM, Carden A, Bergwitz C, Forlino A, Uveges TE, Morris 
MD, Marini JC, Goldstein SA. Brittle IV Mouse Model for Osteogenesis 
Imperfecta IV Demonstrates Postpubertal Adaptations to Improve Whole 
Bone Strength. Journal of Bone and Mineral Research 2004;19: 614-622. 
[16] Uveges TE, Collin-Osdoby P, Cabral WA, Ledgard F, Goldberg L, 
Bergwitz C, Forlino A, Osdoby P, Gronowicz GA, Marini JC. Cellular 
Mechanism of Decreased Bone in Brtl Mouse Model of OI: Imbalance of 
Decreased Osteoblast Function and Increased Osteoclasts and Their 
Precursors. Journal of Bone and Mineral Research 2008;23: 1983-1994. 
[17] Davis MS, Kovacic BL, Marini JC, Shih AJ, Kozloff KM. Increased 
susceptibility to microdamage in Brtl/+ mouse model for osteogenesis 
imperfecta. Bone 2012;50: 784-91. 
[18] Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, 
Rodriguez-Portales J, Downs RW, Jr., Dequeker J, Favus M. Effect of oral 
alendronate on bone mineral density and the incidence of fractures in 
postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis 
Treatment Study Group. N Engl J Med 1995;333: 1437-43. 
[19] Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, 
Keller M, Chesnut CH, 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod 
DW, Miller PD. Effects of risedronate treatment on vertebral and 
nonvertebral fractures in women with postmenopausal osteoporosis: a 
randomized controlled trial. Vertebral Efficacy With Risedronate Therapy 
(VERT) Study Group. JAMA 1999;282: 1344-52. 
[20] Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, 
Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, 
Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, 










Saaf M, Samsioe G, Verbruggen L, Meunier PJ. Intravenous zoledronic acid 
in postmenopausal women with low bone mineral density. N Engl J Med 
2002;346: 653-61. 
[21] Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino 
RP, Rodriguez-Portales JA, Downs RW, Gupta J, Santora AC, Liberman 
UA. Ten years' experience with alendronate for osteoporosis in 
postmenopausal women. N Engl J Med 2004;350: 1189-99. 
[22] Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, 
Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, 
Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, 
Eriksen EF, Cummings SR. Once-yearly zoledronic acid for treatment of 
postmenopausal osteoporosis. N Engl J Med 2007;356: 1809-22. 
[23] Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, 
Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia 
C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, 
Eriksen EF, Boonen S. Zoledronic acid and clinical fractures and mortality 
after hip fracture. N Engl J Med 2007;357: 1799-809. 
[24] Komatsubara S, Mori S, Mashiba T, Li J, Nonaka K, Kaji Y, Akiyama 
T, Miyamoto K, Cao Y, Kawanishi J, Norimatsu H. Suppressed bone 
turnover by long-term bisphosphonate treatment accumulates microdamage 
but maintains intrinsic material properties in cortical bone of dog rib. J Bone 
Miner Res 2004;19: 999-1005. 
[25] Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr 
DB. Suppressed bone turnover by bisphosphonates increases microdamage 
accumulation and reduces some biomechanical properties in dog rib. J Bone 
Miner Res 2000;15: 613-20. 
[26] Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr 
DB. Effects of suppressed bone turnover by bisphosphonates on 
microdamage accumulation and biomechanical properties in clinically 










[27] Li J, Mashiba T, Burr DB. Bisphosphonate treatment suppresses not 
only stochastic remodeling but also the targeted repair of microdamage. 
Calcif Tissue Int 2001;69: 281-6. 
[28] Allen MR, Reinwald S, Burr DB. Alendronate reduces bone 
toughness of ribs without significantly increasing microdamage 
accumulation in dogs following 3 years of daily treatment. Calcif Tissue Int 
2008;82: 354-60. 
[29] Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral 
diaphysis in postmenopausal women taking alendronate. N Engl J Med 
2008;358: 1304-6. 
[30] Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, 
Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, 
Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, 
McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der 
Meulen MC, Weinstein RS, Whyte M. Atypical subtrochanteric and 
diaphyseal femoral fractures: report of a task force of the American Society 
for Bone and Mineral Research. J Bone Miner Res 2010;25: 2267-94. 
[31] Dong XN, Zoghi M, Ran Q, Wang X. Collagen mutation causes 
changes of the microdamage morphology in bone of an OI mouse model. 
Bone 2010;47: 1071-1075. 
[32] Avioli LV. Metabolic Bone Disease and Clinically Related Disorders. 
3rd ed. San Diego: Academic Press; 1998. 
[33] Marini JC, Forlino A, Cabral WA, Barnes AM, Antonio JDS, 
Milgrom S, Hyland JC, Körkkö J, Prockop DJ, Paepe AD, Coucke P, 
Symoens S, Glorieux FH, Roughley PJ, Lund AM, Kuurila-Svahn K, 
Hartikka H, Cohn DH, Krakow D, Mottes M, Schwarze U, Chen D, Yang K, 
Kuslich C, Troendle J, Dalgleish R, Byers PH. Consortium for osteogenesis 
imperfecta mutations in the helical domain of type I collagen: regions rich in 
lethal mutations align with collagen binding sites for integrins and 










[34] Morello R, Bertin TK, Chen Y, Hicks J, Tonachini L, Monticone M, 
Castagnola P, Rauch F, Glorieux FH, Vranka J. CRTAP is required for 
prolyl 3-hydroxylation and mutations cause recessive osteogenesis 
imperfecta. Cell 2006;127: 291. 
[35] Barnes AM, Chang W, Morello R, Cabral WA, Weis M, Eyre DR, 
Leikin S, Makareeva E, Kuznetsova N, Uveges TE, Ashok A, Flor AW, 
Mulvihill JJ, Wilson PL, Sundaram UT, Lee B, Marini JC. Deficiency of 
cartilage-associated protein in recessive lethal osteogenesis imperfecta. New 
England Journal of Medicine, The 2006;355: 2757. 
[36] Cabral WA, Chang W, Barnes AM, Weis M, Scott MA, Leikin S, 
Makareeva E, Kuznetsova NV, Rosenbaum KN, Tifft CJ, Bulas DI, Kozma 
C, Smith PA, Eyre DR, Marini JC. Prolyl 3-hydroxylase 1 deficiency causes 
a recessive metabolic bone disorder resembling lethal/severe osteogenesis 
imperfecta. Nat Genet 2007;39: 359-365. 
[37] Jepsen KJ, Goldstein SA, Kuhn JL, Schaffler MB, Bonadio J. Type-I 
collagen mutation compromises the post-yield behavior of Mov13 long 
bone. Journal of Orthopaedic Research 1996;14: 493. 
[38] Forlino A, Porter FD, Lee EJ, Westphal H, Marini JC. Use of the 
cre/lox recombination system to develop a non-lethal knock-in murine 
model for osteogenesis imperfecta with an α1(I) G349C substitution. Journal 
of Biological Chemistry 1999;274: 37923-37931. 
[39] Lee KCL, Maxwell A, Lanyon LE. Validation of a technique for 
studying functional adaptation of the mouse ulna in response to mechanical 
loading. Bone 2002;31: 407-412. 
[40] Bentolila V, Boyce TM, Fyhrie DP, Drumb R, Skerry TM, Schaffler 
MB. Intracortical remodeling in adult rat long bones after fatigue loading. 
Bone 1998;23: 275-281. 
[41] Torrance AG, Mosley JR, Suswillo RFL, Lanyon LE. Noninvasive 










uncomplicated by trauma or periostal pressure. Calcified Tissue 
International 1994;54: 241. 
[42] Boyce TM, Fyhrie DP, Glotkowski MC, Radin EL, Schaffler MB. 
Damage type and strain mode associations in human compact bone bending 
fatigue. Journal of Orthopaedic Research 1998;16: 322. 
[43] Fritton S, Rubin C. Bone Mechanics Handbook. Boca Raton, FL; 
2001. 
[44] Tami AE, Nasser P, Schaffler MB, Tate MLK. Noninvasive fatigue 
fracture model of the rat ulna. Journal of Orthopaedic Research 2006;21: 
1018. 
[45] Burr DB, Hooser M. Alterations to the en bloc basic fuchsin staining 
protocol for the demonstration of microdamage produced in vivo. Bone 
1995;17: 431. 
[46] Ritchie RO, Koester KJ, Ionova S, Yao W, Lane NE, Ager JW. 
Measurement of the toughness of bone: A tutorial with special reference to 
small animal studies. Bone 2008;43: 798. 
[47] ASTM Standard E-399. Standard test method for linear-elastic plane-
strain fracture toughness KIC of metallic materials. In. West Conshohocken, 
PA: American Society for Testing and Materials:; 2006. 
[48] Kruzic JJ, Kuskowski SJ, Ritchie RO. Simple and accurate fracture 
toughness testing methods for pyrolytic carbon/graphite composites used in 
heart-valve prostheses. Journal of Biomedical Materials Research Part A 
2005;74A: 461-464. 
[49] ASTM Standard E-1820. Standard test method for measurement of 
fracture toughness. In. West Conshohocken, PA; 2006. 
[50] Zahoor A. Ductile Fracture Handbook. Palo Alto: Electric Power 
Research Institute; 1989. 
[51] Takahashi Y. Evaluation of leak-before-break assessment 










stress intensity factor and limit load solutions. The International journal of 
pressure vessels and piping 2002;79: 385. 
[52] Duvall CL, Taylor WR, Weiss D, Wojtowicz AM, Guldberg RE. 
Impaired Angiogenesis, Early Callus Formation, and Late Stage Remodeling 
in Fracture Healing of Osteopontin-Deficient Mice. Journal of Bone and 
Mineral Research 2006;22: 286-297. 
[53] Thurner PJ, Chen CG, Ionova-Martin S, Sun L, Harman A, Porter A, 
Ager Iii JW, Ritchie RO, Alliston T. Osteopontin deficiency increases bone 
fragility but preserves bone mass. Bone 2010;46: 1564-1573. 
[54] Rajachar RM, Chow, D. L., Curtis, C.E., Weissman, N.A., Kohn, 
D.H. Acoustic Emission: Standards and Technology Update. In: S.J. V, 
editor. Use of Acoustic Emission to Characterize Focal and Diffuse 
Microdamage in Bone. West Conshohocken; 1999. 
[55] Zioupos P, Currey JD. Changes in the Stiffness, Strength, and 
Toughness of Human Cortical Bone With Age. Bone 1998;22: 57-66. 
[56] Bonadio J, Saunders TL, Tsai E, Goldstein SA, Morris-Wiman J, 
Brinkley L, Dolan DF, Altschuler RA, Hawkins JE, Bateman JF. Transgenic 
mouse model of the mild dominant form of osteogenesis imperfecta. 
Proceedings of the National Academy of Sciences of the United States of 
America 1990;87: 7145. 
[57] Jepsen K, Schaffler MB, Kuhn JL, Goulet RW, Bonadio J, Goldstein 
SA. Type I collagen mutation alters the strength and fatigue behavior of 
Mov13 cortical tissue. Journal of Biomechanics 1997;30: 1141. 
[58] Uveges TE, Kozloff KM, Ty JM, Ledgard F, Raggio CL, Gronowicz 
G, Goldstein SA, Marini JC. Alendronate Treatment of the Brtl Osteogenesis 
Imperfecta Mouse Improves Femoral Geometry and Load Response Before 
Fracture but Decreases Predicted Material Properties and Has Detrimental 
Effects on Osteoblasts and Bone Formation. Journal of Bone and Mineral 










[59] Boyde A, Travers R, Glorieux FH, Jones SJ. The mineralization 
density of iliac crest bone from children with osteogenesis imperfecta. 
Calcified Tissue International 1999;64: 185. 
[60] Currey J. The effects of ageing and changes in mineral content in 
degrading the toughness of human femora. Journal of Biomechanics 
1996;29: 257. 
[61] Dong X, Guda T, Millwater H, Wang X. Probabilistic failure analysis 
of bone using a finite element model of mineral-collagen composites. 
Journal of Biomechanics 2009;42: 202. 
[62] Burr D, Miller L, Grynpas M, Li J, Boyde A, Mashiba T, Hirano T, 
Johnston C. Tissue mineralization is increased following 1-year treatment 
with high doses of bisphosphonates in dogs. Bone 2003;33: 960. 
[63] Ruppel M, Burr D, Miller L. Chemical makeup of microdamaged 
bone differs from undamaged bone. Bone 2006;39: 318. 
[64] Timlin JA, Carden A, Morris MD, Rajachar RM, Kohn DH. Raman 
Spectroscopic Imaging Markers for Fatigue-Related Microdamage in Bovine 
Bone. Analytical Chemistry 2000;72: 2229-2236. 
[65] Danova NA, Colopy SA, Radtke CL, Kalscheur VL, Markel MD, 
Vanderby R, McCabe RP, Escarcega AJ, Muir P. Degradation of bone 
structural properties by accumulation and coalescence of microcracks. Bone 
2003;33: 197-205. 
[66] Burr DB, Martin RB, Schaffler MB, Radin EL. Bone remodeling in 
response to in vivo fatigue microdamage. Journal of Biomechanics 1985;18: 
189-200. 
[67] Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. 
Science 2000;289: 1508-14. 
[68] Deftos LJ. Treatment of Paget's disease--taming the wild osteoclast. N 










[69] Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. 
Cyclic Administration of Pamidronate in Children with Severe Osteogenesis 
Imperfecta. New England Journal of Medicine 1998;339: 947-952. 
[70] Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives on 
osteogenesis imperfecta. Nature Reviews Endocrinology 2011;7: 540-557. 
[71] Brenner RE, Vetter U, Bollen A-M, Mörike M, Eyre DR. Bone 
resorption assessed by immunoassay of urinary cross-linked collagen 
peptides in patients with osteogenesis imperfecta. Journal of Bone and 
Mineral Research 1994;9: 993-997. 
[72] Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson D, 
Golub E, Rodan G. Bisphosphonate action. Alendronate localization in rat 
bone and effects on osteoclast ultrastructure. Journal of Clinical 
Investigation 1991;88: 2095. 
[73] Azuma Y, Sato H, Oue Y, Okabe K, Ohta T, Tsuchimoto M, Kiyoki 
M. Alendronate distributed on bone surfaces inhibits osteoclastic bone 
resorption< i> in vitro</i> and in experimental hypercalcemia models. Bone 
1995;16: 235-245. 
[74] Plotkin LW, Robert S; Parfitt, A. Michael; Roberson, Paula K.; 
Manolagas, Stavros C; Bellido, Teresita. Prevention of osteocyte and 
osteoblast apoptosis by bisphosphonates and calcitonin. Journal of Clinical 
Investigation 1999;104: 1363-1374. 
[75] Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tatò L, Viapiana 
O, Adami S. Intravenous Neridronate in Children With Osteogenesis 
Imperfecta: A Randomized Controlled Study. Journal of Bone and Mineral 
Research 2005;20: 758-763. 
[76] Seikaly MG, Kopanati S, Salhab N, Waber P, Patterson D, Browne R, 
Herring JA. Impact of alendronate on quality of life in children with 











[77] Letocha AD, Cintas HL, Troendle JF, Reynolds JC, Cann CE, 
Chernoff EJ, Hill SC, Gerber LH, Marini JC. Controlled Trial of 
Pamidronate in Children With Types III and IV Osteogenesis Imperfecta 
Confirms Vertebral Gains but Not Short‐Term Functional Improvement. 
Journal of Bone and Mineral Research 2005;20: 977-986. 
[78] Rauch F, Munns CF, Land C, Cheung M, Glorieux FH. Risedronate in 
the Treatment of Mild Pediatric Osteogenesis Imperfecta: A Randomized 
Placebo‐Controlled Study. Journal of Bone and Mineral Research 2009;24: 
1282-1289. 
[79] Komatsubara S, Mori S, Mashiba T, Li J, Nonaka K, Kaji Y, Akiyama 
T, Miyamoto K, Cao Y, Kawanishi J. Suppressed Bone Turnover by Long‐
Term Bisphosphonate Treatment Accumulates Microdamage but Maintains 
Intrinsic Material Properties in Cortical Bone of Dog Rib. Journal of Bone 
and Mineral Research 2005;20: 2066-2073. 
[80] Mashiba T, Turner C, Hirano T, Forwood M, Johnston C, Burr D. 
Effects of suppressed bone turnover by bisphosphonates on microdamage 
accumulation and biomechanical properties in clinically relevant skeletal 
sites in beagles. Bone 2001;28: 524-531. 
[81] Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr 
DB. Suppressed bone turnover by bisphosphonates increases microdamage 
accumulation and reduces some biomechanical properties in dog rib. Journal 
of Bone and Mineral Research 2000;15: 613-620. 
[82] Allen MR, Reinwald S, Burr DB. Alendronate reduces bone 
toughness of ribs without significantly increasing microdamage 
accumulation in dogs following 3 years of daily treatment. Calcified Tissue 
International 2008;82: 354-360. 
[83] Evans K, Lau S, Oberbauer A, Martin R. Alendronate affects long 
bone length and growth plate morphology in the< i> oim</i> mouse model 










[84] Misof BM, Roschger P, Baldini T, Raggio CL, Zraick V, Root L, 
Boskey AL, Klaushofer K, Fratzl P, Camacho NP. Differential effects of 
alendronate treatment on bone from growing osteogenesis imperfecta and 
wild-type mouse. Bone 2005;36: 150-158. 
[85] Forlino A, Porter FD, Lee EJ, Westphal H, Marini JC. Use of the 
Cre/lox recombination system to develop a non-lethal knock-in murine 
model for osteogenesis imperfecta with an α1(I) G349C substitution. 
Variability in phenotype in BrtlIV mice. J Biol Chem 1999;274: 37923-31. 
[86] Davis MS, Kovacic BL, Marini JC, Shih AJ, Kozloff KM. Increased 
susceptibility to microdamage in Brtl/+ mouse model for osteogenesis 
imperfecta. Bone 2012;50: 784-791. 
[87] McCarthy EA, Raggio CL, Hossack MD, Miller EA, Jain S, Boskey 
AL, Camacho NP. Alendronate Treatment for Infants with Osteogenesis 
Imperfecta: Demonstration of Efficacy in a Mouse Model. Pediatr Res 
2002;52: 660-670. 
[88] Uveges T, Kozloff KM, Ty JM, Ledgard F, Raggio CL, Gronowicz G, 
Goldstein SA, Marini JC. Alendronate treatment of Brtl osteogenesis 
imperfecta mouse improves femoral geometry and load response before 
fracture but has detrimental effects on osteoblasts and bone formation and 
decreases predicted material properties. Journal of Bone and Mineral 
Research 2009;24: 849-859. 
[89] Allen MR, Burr DB. Three years of alendronate treatment results in 
similar levels of vertebral microdamage as after one year of treatment. 
Journal of Bone and Mineral Research 2007;22: 1759-1765. 
[90] Allen MR, Iwata K, Sato M, Burr DB. Raloxifene enhances vertebral 
mechanical properties independent of bone density. Bone 2006;39: 1130-
1135. 
[91] Allen M, Gineyts E, Leeming D, Burr D, Delmas P. Bisphosphonates 
alter trabecular bone collagen cross-linking and isomerization in beagle dog 










[92] Viguet-Carrin S, Roux J, Arlot M, Merabet Z, Leeming D, Byrjalsen 
I, Delmas P, Bouxsein M. Contribution of the advanced glycation end 
product pentosidine and of maturation of type I collagen to compressive 
biomechanical properties of human lumbar vertebrae. Bone 2006;39: 1073-
1079. 
[93] Hernandez CJ, Tang SY, Baumbach BM, Hwu PB, Sakkee AN, van 
der Ham F, DeGroot J, Bank RA, Keaveny TM. Trabecular microfracture 
and the influence of pyridinium and non-enzymatic glycation-mediated 
collagen cross-links. Bone 2005;37: 825-832. 
[94] Wang X, Shen X, Li X, Mauli Agrawal C. Age-related changes in the 
collagen network and toughness of bone. Bone 2002;31: 1-7. 
[95] Boxberger J, Vashishth D. Nonenzymatic glycation affects bone 
fracture by modifying creep and inelastic properties of collagen. Trans 
Orthop Res Soc 2004;29. 
[96] Tang SY, Zeenath U, Vashishth D. Effects of non-enzymatic 
glycation on cancellous bone fragility. Bone 2007;40: 1144-1151. 
[97] Catanese J, Bank R, TeKoeppele J, Keaveny T. Increased cross-
linking by non-enzymatic glycation reduces the ductility of bone and bone 
collagen. ASME-PUBLICATIONS-BED 1999;42: 267-268. 
[98] Wu P, Koharski C, Nonnenmann H, Vashishth D. Loading on non-
enzymatically glycated and damaged bone results in an instantaneous 
fracture. Trans Orthop Res Soc 2003;28: 404. 
[99] Grissom LE, Harcke HT. Radiographic features of bisphosphonate 
therapy in pediatric patients. Pediatric radiology 2003;33: 226-229. 
[100] van Persijn van Meerten EL, Kroon HM, Papapoulos SE. Epi- and 
metaphyseal changes in children caused by administration of 
bisphosphonates. Radiology 1992;184: 249-254. 
[101] Åström E, Söderhäll S. Beneficial effect of long term intravenous 
bisphosphonate treatment of osteogenesis imperfecta. Archives of disease in 










[102] Solomon CG. Bisphosphonates and osteoporosis. The New England 
journal of medicine 2002;346: 642. 
[103] Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. 
Journal of Clinical Investigation 1996;97: 2692. 
[104] Marini JC. Do bisphosphonates make children's bones better or 
brittle? The New England journal of medicine 2003;349: 423. 
[105] Laor T, Jaramillo D. Metaphyseal abnormalities in children: 
pathophysiology and radiologic appearance. AJR. American journal of 
roentgenology 1993;161: 1029-1036. 
[106] Bikle DD, Morey‐Holton ER, Doty SB, Currier PA, Tanner SJ, 
Halloran BP. Alendronate increases skeletal mass of growing rats during 
unloading by inhibiting resorption of calcified cartilage. Journal of Bone and 
Mineral Research 1994;9: 1777-1787. 
[107] Camacho NP, Raggio CL, Doty SB, Root L, Zraick V, Ilg WA, 
Toledano TR, Boskey AL. A Controlled Study of the Effects of Alendronate 
in a Growing Mouse Model of Osteogenesis Imperfecta. Calcified Tissue 
International 2001;69: 94-101. 
[108] Rubin C, Lanyon L. Regulation of bone mass by mechanical strain 
magnitude. Calcified Tissue International 1985;37: 411-417. 
[109] Biewener AA. Musculoskeletal design in relation to body size. 
Journal of Biomechanics 1991;24, Supplement 1: 19-29. 
[110] Marini JC. Should children with osteogenesis imperfecta be treated 
with bisphosphonates? Nature Clinical Practice Endocrinology & 
Metabolism 2006;2: 14+. 
[111] Fielding JW. Subtrochanteric fractures. Clinical Orthopaedics and 
Related Research 1973;92: 86-99. 
[112] Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers 
R, Glorieux FH. Pamidronate treatment of severe osteogenesis imperfecta in 
children under 3 years of age. Journal of Clinical Endocrinology & 










[113] Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, 
Rodriguez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker 
RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB. 
Effect of Oral Alendronate on Bone Mineral Density and the Incidence of 
Fractures in Postmenopausal Osteoporosis. New England Journal of 
Medicine 1995;333: 1437-1444. 
[114] Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-
Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC. Effect 
of alendronate on risk of fracture in women with low bone density but 
without vertebral fractures. JAMA: The Journal of the American Medical 
Association 1998;280: 2077-2082. 
[115] Komatsubara S, Mori S, Mashiba T, Li J, Nonaka K, Kaji Y, Akiyama 
T, Miyamoto K, Cao Y, Kawanishi J, Norimatsu H. Suppressed Bone 
Turnover by Long-Term Bisphosphonate Treatment Accumulates 
Microdamage but Maintains Intrinsic Material Properties in Cortical Bone of 
Dog Rib. Journal of Bone and Mineral Research 2005;20: 2066-2073. 
[116] Mashiba T, Mori S, Komatsubara S, Cao Y, Manabe T, Norimatsu H, 
Burr DB. THe effects of suppressed bone remodeling by bisphosphonates on 
microdamage accumulation and degree of mineralization in the cortical bone 
of dog rib. Journal of Bone and Mineral Metabolism 2005;23: 36-42. 
[117] Kwek EBK, Goh SK, Koh JSB, Png MA, Howe TS. An emerging 
pattern of subtrochanteric stress fractures: A long-term complication of 
alendronate therapy? Injury 2008;39: 224-231. 
[118] Allen MR, Iwata K, Phipps R, Burr DB. Alterations in canine 
vertebral bone turnover, microdamage accumulation, and biomechanical 
properties following 1-year treatment with clinical treatment doses of 
risedronate or alendronate. Bone 2006;39: 872-879. 
[119] Yamagami Y, Mashiba T, Iwata K, Tanaka M, Nozaki K, Yamamoto 










Microdamage accumulation, Degree of mineralization and bone mechanical 
properties in ovariectomized cynomolgus monkeys. Bone 2013;54: 1-7. 
[120] Tang SY, Allen MR, Phipps R, Burr DB, Vashishth D. Changes in 
non-enzymatic glycation and its association with altered mechanical 
properties following 1-year treatment with risedronate or alendronate. 
Osteoporosis International 2009;20: 887-894. 
[121] Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. 
Cyclic administration of pamidronate in children with severe osteogenesis 
imperfecta. N Engl J Med 1998;339: 947-52. 
[122] Allen MR, Gineyts E, Leeming DJ, Burr DB, Delmas PD. 
Bisphosphonates alter trabecular bone collagen cross-linking and 
isomerization in beagle dog vertebra. Osteoporos Int 2008;19: 329-37. 
[123] Tang SY, Allen MR, Phipps R, Burr DB, Vashishth D. Changes in 
non-enzymatic glycation and its association with altered mechanical 
properties following 1-year treatment with risedronate or alendronate. 
Osteoporos Int 2009;20: 887-94. 
[124] Saito M, Mori S, Mashiba T, Komatsubara S, Marumo K. Collagen 
maturity, glycation induced-pentosidine, and mineralization are increased 
following 3-year treatment with incadronate in dogs. Osteoporos Int 
2008;19: 1343-54. 
[125] Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. 
Alendronate increases bone strength by increasing the mean degree of 
mineralization of bone tissue in osteoporotic women. Bone 2000;27: 687-94. 
[126] Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer 
K. Alendronate increases degree and uniformity of mineralization in 
cancellous bone and decreases the porosity in cortical bone of osteoporotic 
women. Bone 2001;29: 185-191. 
[127] O'Brien FJ, Taylor D, Lee TC. Microcrack accumulation at different 











[128] O'Brien FJ, Taylor D, Clive Lee T. The effect of bone microstructure 
on the initiation and growth of microcracks. J Orthop Res 2005;23: 475-80. 
[129] Verborgt O, Gibson GJ, Schaffler MB. Loss of Osteocyte Integrity in 
Association with Microdamage and Bone Remodeling After Fatigue In 
Vivo. Journal of Bone and Mineral Research 2000;15: 60-67. 
[130] Verborgt O, Tatton NA, Majeska RJ, Schaffler MB. Spatial 
distribution of Bax and Bcl-2 in osteocytes after bone fatigue: 
complementary roles in bone remodeling regulation? J Bone Miner Res 
2002;17: 907-14. 
[131] Herman BC, Cardoso L, Majeska RJ, Jepsen KJ, Schaffler MB. 
Activation of bone remodeling after fatigue: differential response to linear 
microcracks and diffuse damage. Bone 2010;47: 766-72. 
[132] Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, 
Bellido T. Prevention of osteocyte and osteoblast apoptosis by 
bisphosphonates and calcitonin. J Clin Invest 1999;104: 1363-74. 
[133] Kennedy OD, Herman BC, Laudier DM, Majeska RJ, Sun HB, 
Schaffler MB. Activation of resorption in fatigue-loaded bone involves both 
apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte 
populations. Bone 2012;50: 1115-22. 
[134] Mulcahy LE, Taylor D, Lee TC, Duffy GP. RANKL and OPG activity 
is regulated by injury size in networks of osteocyte-like cells. Bone 2011;48: 
182-8. 
[135] Follet H, Li J, Phipps RJ, Hui S, Condon K, Burr DB. Risedronate and 
alendronate suppress osteocyte apoptosis following cyclic fatigue loading. 
Bone 2007;40: 1172-7. 
[136] Plotkin LI, Manolagas SC, Bellido T. Dissociation of the pro-
apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic 
effects on osteoblasts/osteocytes with novel analogs. Bone 2006;39: 443-52. 
[137] Plotkin LI, Lezcano V, Thostenson J, Weinstein RS, Manolagas SC, 










bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res 
2008;23: 1712-21. 
[138] Tami AE, Nasser P, Verborgt O, Schaffler MB, Knothe Tate ML. The 
role of interstitial fluid flow in the remodeling response to fatigue loading. J 
Bone Miner Res 2002;17: 2030-7. 
[139] Muir P, Sample SJ, Barrett JG, McCarthy J, Vanderby R, Jr., Markel 
MD, Prokuski LJ, Kalscheur VL. Effect of fatigue loading and associated 
matrix microdamage on bone blood flow and interstitial fluid flow. Bone 
2007;40: 948-56. 
[140] Kozloff KM, Weissleder R, Mahmood U. Non-invasive optical 
detection of bone mineral. J Bone Miner Res 2007;22: 1208-16. 
[141] Kozloff KM, Volakis LI, Marini JC, Caird MS. Near-infrared 
fluorescent probe traces bisphosphonate delivery and retention in vivo. J 
Bone Miner Res 2010;25: 1748-58. 
[142] Li Y, Si R, Feng Y, Chen HH, Zou L, Wang E, Zhang M, Warren HS, 
Sosnovik DE, Chao W. Myocardial ischemia activates an injurious innate 
immune signaling via cardiac heat shock protein 60 and Toll-like receptor 4. 
Journal of Biological Chemistry 2011;286: 31308-31319. 
[143] Smith BA, Gammon ST, Xiao S, Wang W, Chapman S, McDermott 
R, Suckow MA, Johnson JR, Piwnica-Worms D, Gokel GW. In Vivo 
Optical Imaging of Acute Cell Death Using a Near-Infrared Fluorescent 
Zinc− Dipicolylamine Probe. Molecular pharmaceutics 2011;8: 583-590. 
[144] Chen R, Zheng X, Qian H, Wang X, Wang J, Jiang X. Combined 
near-IR photothermal therapy and chemotherapy using gold-
nanorod/chitosan hybrid nanospheres to enhance the antitumor effect. 
Biomaterials Science 2013;1: 285-293. 
[145] Verborgt O, Tatton NA, Majeska RJ, Schaffler MB. Spatial 
Distribution of Bax and Bcl-2 in Osteocytes After Bone Fatigue: 
Complementary Roles in Bone Remodeling Regulation? Journal of Bone 










[146] Follet H, Li J, Phipps RJ, Hui S, Condon K, Burr DB. Risedronate and 
alendronate suppress osteocyte apoptosis following cyclic fatigue loading. 
Bone 2007;40: 1172-1177. 
[147] Burger EH. Mechanotransduction in bone-role of the 
lacunocanalicular network. The FASEB journal 1999;13: 101. 
[148] Tanaka K, Matsuo T, Ohta M, Sato T, Tezuka K, Nijweide P, Katoh 
Y, Hakeda Y, Kumegawa M. Time-lapse microcinematography of 
osteocytes. Mineral and electrolyte metabolism 1995;21: 189. 
[149] Bronckers A, Goei W, Luo G, Karsenty G, D'souza R, Lyaruu D, 
Burger E. DNA fragmentation during bone formation in neonatal rodents 
assessed by transferase‐mediated end labeling. Journal of Bone and Mineral 
Research 1996;11: 1281-1291. 
[150] Gu G, Mulari M, Peng Z, Hentunen TA, Väänänen HK. Death of 
osteocytes turns off the inhibition of osteoclasts and triggers local bone 
resorption. Biochemical and biophysical research communications 
2005;335: 1095-1101. 
[151] Maejima-Ikeda A, Aoki M, Tsuritani K, Kamioka K, Hiura K, 
Miyoshi T, Hara H, Takano-Yamamoto T, Kumegawa M. Chick osteocyte-
derived protein inhibits osteoclastic bone resorption. Biochem. J 1997;322: 
245-250. 
[152] Heino TJ, Hentunen TA, Väänänen HK. Osteocytes inhibit 
osteoclastic bone resorption through transforming growth factor‐β: 
Enhancement by estrogen*. Journal of cellular biochemistry 2002;85: 185-
197. 
[153] Noble B, Stevens H, Loveridge N, Reeve J. Identification of apoptotic 
changes in osteocytes in normal and pathological human bone. Bone 
1997;20: 273-282. 
[154] Knothe Tate ML. In vivo demonstration of load-induced fluid flow in 
the rat tibia and its potential implications for processes associated with 










[155] Turek J, Ebetino FH, Lundy M, Sun S, Kashemirov B, McKenna C, 
Gallant M, Plotkin L, Bellido T, Duan X, Triffitt J, Russell RG, Burr D, 
Allen M. Bisphosphonate Binding Affinity Affects Drug Distribution in 
Both Intracortical and Trabecular Bone of Rabbits. Calcified Tissue 
International 2012;90: 202-210. 
[156] Roelofs AJ, Stewart CA, Sun S, Blazewska KM, Kashemirov BA, 
McKenna CE, Russell RG, Rogers MJ, Lundy MW, Ebetino FH, Coxon FP. 
Influence of bone affinity on the skeletal distribution of fluorescently labeled 
bisphosphonates in vivo. J Bone Miner Res 2012;27: 835-47. 
[157] Roelofs AJ, Coxon FP, Ebetino FH, Lundy MW, Henneman ZJ, 
Nancollas GH, Sun S, Blazewska KM, Bala JL, Kashemirov BA, Khalid 
AB, McKenna CE, Rogers MJ. Fluorescent risedronate analogues reveal 
bisphosphonate uptake by bone marrow monocytes and localization around 
osteocytes in vivo. J Bone Miner Res 2010;25: 606-16. 
[158] Noble BS, Peet N, Stevens HY, Brabbs A, Mosley JR, Reilly GC, 
Reeve J, Skerry TM, Lanyon LE. Mechanical loading: biphasic osteocyte 
survival and targeting of osteoclasts for bone destruction in rat cortical bone. 
American Journal of Physiology-Cell Physiology 2003;284: C934-C943. 
[159] Wang Q, Marini JC. Antisense oligodeoxynucleotides selectively 
suppress expression of the mutant alpha 2 (I) collagen allele in type IV 
osteogenesis imperfecta fibroblasts. A molecular approach to therapeutics of 
dominant negative disorders. Journal of Clinical Investigation 1996;97: 448. 
[160] Deyle DR, Khan IF, Ren G, Wang P-R, Kho J, Schwarze U, Russell 
DW. Normal collagen and bone production by gene-targeted human 
osteogenesis imperfecta iPSCs. Molecular Therapy 2011;20: 204-213. 
[161] Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, 
Westmore MS, Ma YL, Nold JB. Skeletal changes in rats given daily 
subcutaneous injections of recombinant human parathyroid hormone (1-34) 











[162] Bargman R, Posham R, Boskey A, DiCarlo E, Raggio C, Pleshko N. 
Comparable outcomes in fracture reduction and bone properties with 
RANKL inhibition and alendronate treatment in a mouse model of 
osteogenesis imperfecta. Osteoporosis International 2012;23: 1141-1150. 
[163] Sinder BP, Eddy MM, Ominsky MS, Caird MS, Marini JC, Kozloff 
KM. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse 
model of osteogenesis imperfecta. Journal of Bone and Mineral Research 
2013;28: 73-80. 
[164] Kurata K, Heino TJ, Higaki H, Väänänen HK. Bone Marrow Cell 
Differentiation Induced by Mechanically Damaged Osteocytes in 3D Gel-
Embedded Culture. Journal of Bone and Mineral Research 2006;21: 616-
625. 
[165] Löhler J, Timpl R, Jaenisch R. Embryonic lethal mutation in mouse 
collagen I gene causes rupture of blood vessels and is associated with 
erythropoietic and mesenchymal cell death. Cell 1984;38: 597-607. 
 
 
